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Abstract
The immune response is a complex mechanism that can be triggered by biological or physical
stresses on the organism. However an excessive and dys-regulated inflammatory response
may lead to sepsis, a critical state, promoting tissue damage, organ dysfunction or even
death.
The main objective in this dissertation is to derive a strategy consisting of manipulating
pro and anti-inflammatory mediators in order to direct the state of a virtual patient to a
healthy equilibrium, after some disturbance from health due to infection. Two key challenges
need to be addressed in solving such a problem: estimating the unmeasurable states of
the inflammatory model as well as the model’s unknown rate parameters; and second,
determining an appropriate strategy to effectively control the response.
We initially study the nonlinear controllability, observability and identifiability of the
inflammatory immune model. Then, we address the first challenge by comparing the
performance of various nonlinear filters for state estimation in the presence of noise and
incomplete information. For parameter estimation, a recently introduced approximate
Markov chain Monte Carlo approach known as the Particle Metropolis- Hastings method is
used. To control the highly nonlinear model, various model-based optimization approaches
were investigated in which the control strategy is derived in terms of pro-inflammatory and
anti-inflammatory response doses. Due to parameter variability and the difficult practical
task of obtaining accurate state and parameter estimates in real time, a new model-free
control methodology and its intelligent controllers is explored. The method does not rely on
any precise modeling and the identification of each parameter of the inflammatory immune
model is no longer needed for control design. The various methods are compared for
iv
performance to adequately control the responses in a diverse patient population as well
as the clinical feasibility of the derived control protocol from the approach used.
v
Table of Contents
1 Introduction 1
1.1 Motivation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.2 Background and Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.2.1 State and Parameter Estimation . . . . . . . . . . . . . . . . . . . . . 3
1.2.2 Optimal Control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.2.3 Model Free Control . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.3 Summary of Contributions . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.4 Thesis Organisation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2 Mathematical model 10
2.1 A virtual patient . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
3 Nonlinear Controllability and Observability 15
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
3.2 Nonlinear Controllability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
3.2.1 Controllability Rank Condition: . . . . . . . . . . . . . . . . . . . . . 16
3.3 Nonlinear Observability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
3.3.1 Observability Rank Condition . . . . . . . . . . . . . . . . . . . . . . 19
3.4 Parameter identifiability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
3.4.1 Identifiability rank condition . . . . . . . . . . . . . . . . . . . . . . . 22
4 Nonlinear State Estimation 24
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
vi
4.2 The extended Kalman filter (EKF) . . . . . . . . . . . . . . . . . . . . . . . 25
4.3 Unscented Kalman filtler . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
4.4 Particle filter (PF) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
4.4.1 Importance Sampling . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
4.5 Simulation Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
4.5.1 Further simulation results with the particle filter . . . . . . . . . . . . 36
4.6 Concluding remarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
5 Nonlinear Parameter Estimation 40
5.1 Overview of the PMH sampler . . . . . . . . . . . . . . . . . . . . . . . . . . 41
5.1.1 Markov chain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
5.1.2 Approximating the acceptance probability . . . . . . . . . . . . . . . 43
5.1.3 PMH algorithm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
5.2 Numerical simulations for parameter inference . . . . . . . . . . . . . . . . . 45
5.2.1 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
6 Nonlinear control 55
6.1 Backstepping control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
6.1.1 Backstepping control for the immune model . . . . . . . . . . . . . . 56
6.1.2 Dynamic extension for input output decoupling . . . . . . . . . . . . 58
6.1.3 Dynamic extension with backstepping . . . . . . . . . . . . . . . . . . 60
6.2 Immune Therapeutic Strategies Using Optimal Controls with L1 and L2 Type
Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
6.2.1 The Optimal Control Problem . . . . . . . . . . . . . . . . . . . . . . 65
6.2.2 Existence of an optimal control . . . . . . . . . . . . . . . . . . . . . 68
6.2.3 Numerical solution of optimal control problem . . . . . . . . . . . . . 70
6.2.4 Optimal Control with L1 type Objective . . . . . . . . . . . . . . . . 72
6.2.5 Optimal Control with L2 type Objective . . . . . . . . . . . . . . . . 84
6.3 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
vii
7 Towards a model free feedback control synthesis for treating acute
inflammations 95
7.1 Justification of the model-free approach: A brief sketch . . . . . . . . . . . . 96
7.1.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
7.1.2 Intelligent controllers . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
7.1.3 Justification of the ultra-local model . . . . . . . . . . . . . . . . . . 97
7.1.4 Closing the loop . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
7.1.5 Estimation of F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
7.2 Computer Simulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
7.2.1 Control design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
7.2.2 Results without noise corruption . . . . . . . . . . . . . . . . . . . . 103
7.2.3 Results with noise corruption . . . . . . . . . . . . . . . . . . . . . . 108
7.2.4 Further simulation with model free control . . . . . . . . . . . . . . . 111
7.3 Concluding remarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
8 Conclusions and future work 114
Bibliography 116
Vita 128
viii
List of Tables
4.1 Variability of the model parameters . . . . . . . . . . . . . . . . . . . . . . . 34
4.2 RMSE and NEES for Patient 1 . . . . . . . . . . . . . . . . . . . . . . . . . 36
4.3 RMSE and NEES for Patient 2 . . . . . . . . . . . . . . . . . . . . . . . . . 36
4.4 RMSE and NEES for Patient 3 . . . . . . . . . . . . . . . . . . . . . . . . . 36
4.5 RMSE and NEES for Patient 4 . . . . . . . . . . . . . . . . . . . . . . . . . 36
4.6 The logarithms of the absolute value of the error (bias) and the mean square
error for various values of particles . . . . . . . . . . . . . . . . . . . . . . . 38
5.1 True parameters together with their variability range . . . . . . . . . . . . . 46
6.1 Parameters of the algebraically rearranged immune model with control terms
as given in (6.73). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
7.1 Result of the immune therapy . . . . . . . . . . . . . . . . . . . . . . . . . . 106
7.2 Result of the immune therapy with measurement noise . . . . . . . . . . . . 111
ix
List of Figures
2.1 Diagram of natural and enhanced immune dynamics in response to pathogenic
stimulus. P : replicating pathogen, N : early pro-inflammatory immune
mediators, D: marker of tissue damage/dysfunction caused by inflammatory
response, Ca: inhibitory anti-inflammatory mediators, ua and up: time-
varying input controls for the anti- and pro-inflammatory therapy, respec-
tively. Solid lines with arrow heads and dashed lines with nodes/circular
heads represent upregulation and inhibition, respectively. . . . . . . . . . . . 12
2.2 Time courses of system states for natural (open loop) response for virtual
patient 1 (solid curves), resulting in a (septic death outcome) and for virtual
patient 2 (dashed curves), resulting in an (aseptic death outcome.) . . . . . . 14
4.1 State estimation (EKF, UKF, PF) for patient 1 . . . . . . . . . . . . . . . . 35
4.2 Squared Error (SE) of estimated states for Patient 1 . . . . . . . . . . . . . 35
4.3 State estimation (EKF, UKF, PF) for patient 3 . . . . . . . . . . . . . . . . 37
4.4 Squared Error (SE) of estimated states for Patient 3 . . . . . . . . . . . . . 37
4.5 The logarithms of the absolute value of the error (bias) and the mean square
error for various values of particles . . . . . . . . . . . . . . . . . . . . . . . 38
4.6 A simulated set of 100 realization (dotted line) for the pathogen (P ), Pro-
inflammatory mediator (N), the Damage (D) and the anti-inflammatory
mediator (Ca) together with their corresponding true state (slide line) using
particle filter with N = 20, σv = 0.0001, σe = 0.001 . . . . . . . . . . . . . . 39
x
5.1 The estimate of the target distribution using PMH algorithm. Upper: The
estimate of πkpg(kpg) presented as a histogram and kernel density estimate
(solid line). Middle: The state of the Markov chain for 500 iterations. Lower:
the estimated ACF for the Markov chain. Dotted lines in the upper and
middle plot indicate the estimate of the posterior mean (kpgmean = 0.549).
The dotted lines in the lower plot indicate the 95% confidence intervals of the
ACF coefficients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
5.2 The estimate of the target distribution using PMH algorithm. Upper: The
estimate of πkpg(kpg) presented as a histogram and kernel density estimate
(solid line). Middle: The state of the Markov chain for 500 iterations. Lower:
the estimated ACF for the Markov chain. Dotted lines in the upper and
middle plot indicate the estimate of the posterior mean (kpgmean = 0.549).
The dotted lines in the lower plot indicate the 95% confidence intervals of the
ACF coefficients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
5.3 The estimate of the target distribution using PMH algorithm. Upper: The
estimate of πkcn(kcn) presented as a histogram and kernel density estimate
(solid line). Middle: The state of the Markov chain for 500 iterations. Lower:
the estimated ACF for the Markov chain. Dotted lines in the upper and
middle plot indicate the estimate of the posterior mean (kcnmean = 0.0368).
The dotted lines in the lower plot indicate the 95% confidence intervals of the
ACF coefficients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
5.4 The estimate of the target distribution using PMH algorithm. Upper: The
estimate of πknd(knd) presented as a histogram and kernel density estimate
(solid line). Middle: The state of the Markov chain for 500 iterations. Lower:
the estimated ACF for the Markov chain. Dotted lines in the upper and
middle plot indicate the estimate of the posterior mean (kndmean = 0.0292).
The dotted lines in the lower plot indicate the 95% confidence intervals of the
ACF coefficients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
xi
5.5 The estimate of the target distribution using PMH algorithm. Upper: The
estimate of πKnp(knp) presented as a histogram and kernel density estimate
(solid line). Middle: The state of the Markov chain for 500 iterations. Lower:
the estimated ACF for the Markov chain. Dotted lines in the upper and
middle plot indicate the estimate of the posterior mean (knpmean = 0.118).
The dotted lines in the lower plot indicate the 95% confidence intervals of the
ACF coefficients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
5.6 The estimate of the target distribution using PMH algorithm. Upper: The
estimate of πKnn(knn) presented as a histogram and kernel density estimate
(solid line). Middle: The state of the Markov chain for 500 iterations. Lower:
the estimated ACF for the Markov chain. Dotted lines in the upper and
middle plot indicate the estimate of the posterior mean (knnmean = 0.034).
The dotted lines in the lower plot indicate the 95% confidence intervals of the
ACF coefficients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
6.1 (a)-(d) Time courses for optimal states, (e)-(f) control states, and (g)-(h) the
switching functions φ1 and φ2. Control constraints in this simulation which
uses an L1 type objective are 0 ≤ up ≤ 0.5, 0 ≤ ua ≤ 0.62. . . . . . . . . . . 76
6.2 Comparison of basic optimal control with an approximate control for the L1
objective case with dosing constraints of 0 ≤ up ≤ 0.5 and 0 ≤ ua ≤ 0.62. (a)
Generated optimal controls up and ua and (b) corresponding optimal states.
(c) Generated optimal control up and approximation of optimal control ua
and (d) corresponding states. The time frame displayed in both plots (a) and
(c) of the control doses is for tf = 40 hours since afterward the values of both
controls are zero. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
xii
6.3 Comparison of basic optimal control with an approximate control for the L1
objective case with upper bounds on dosing constraints given as upmax =
0.25 and uamax = 0.31. (a) Generated optimal controls up and ua and
(b) corresponding optimal states. (c) Generated optimal control up and
approximation of optimal control ua and (d) corresponding states. The time
frame displayed in both plots (a) and (c) of the control doses is for tf = 40
hours since afterward the values of both controls are zero. . . . . . . . . . . . 80
6.4 Optimal doses and corresponding state trajectories for an L1 type objective
with state constraints 0 ≤ N(t) ≤ 0.5, 0 ≤ Ca ≤ 0.62 together with dosing
constraints 0 ≤ up ≤ 0.5 and 0 ≤ ua ≤ 0.62. (a) Dosing profiles for up and
ua controls that lead to (b) a healthy outcome as all states decrease toward
background levels. The time frame displayed in (a) of the control doses is for
tf = 40 hours since afterward the values of both controls are zero. . . . . . . 83
6.5 (a) Optimal doses and (b) corresponding state trajectories for a quadratic
type objective with mixed control state inequality constraints 0 ≤ up(t) ≤
0.5−N(t), 0 ≤ ua(t) ≤ 0.62− Ca(t). The time frame displayed in (a) of the
control doses is for tf = 40 hours since afterward the values of both controls
are zero. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
6.6 (a) Optimal doses and (b) corresponding state trajectories for a quadratic
type objective with state path constraints 0 ≤ N(t) ≤ 0.5, 0 ≤ Ca ≤ 0.62.
The time frame displayed in (a) of the control doses is for tf = 40 hours since
afterward the values of both controls are zero. . . . . . . . . . . . . . . . . . 89
6.7 Numerical solutions of the state and control constrained problem with L2
objective. Top row: control ua(t) and constrained anti-inflammatory state
Ca(t). Bottom row: The scaled adjoint λ4 corresponding to the state Ca(t)
together with the multiplier λsa corresponding to the constraint S(x(t)) =
Ca(t)−0.62. The time frame displayed in the figures is for tf = 40 hours since
afterward the values of the control inputs are zero. . . . . . . . . . . . . . . 92
7.1 Block diagram of the model free control design . . . . . . . . . . . . . . . . . 104
xiii
7.2 Dashed (- -) curves in the panels for the variables N and Ca denote the
reference trajectories used in the simulation. The various colored curves
display the closed loop state responses for the set of 141 septic patients, of
which 92 were cured. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
7.3 Time evolution of the control up and ua for the set of septic patients. The
zoomed plot for up provides more details on the duration of the control dose,
the x-axis is shown for two hours only since it is zero for the remaining time 105
7.4 Dashed (- -) curves in the panels for the variables N and Ca denote the
reference trajectories used in the simulation. The various colored curves
display the closed loop state responses for the set of 228 aseptic patients,
of which 188 were cured. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
7.5 Time evolution of the control up and ua for the set of septic patients. The
zoomed plot for up provides more details on the duration of the control dose,
the x-axis is shown for two hours only since it is zero for most of the time . . 107
7.6 Dashed (- -) curves in the panels for the variables N and Ca denote the
reference trajectories used in the simulation. The various colored curves
display the closed loop state responses for the set of 141 aseptic patients, of
which 90 were cured. Note that the measurements N and Ca were corrupted
with Gaussian noise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
7.7 Time evolution of the control up and ua for the set of aseptic patients when the
measurements N and Ca were corrupted with Gaussian noise. The zoomed
plot for up provides more details on the duration of the control dose, the x-axis
is shown for two hours only since it is zero for the remaining time . . . . . . 109
7.8 Dashed (- -) curves in the panels for the variables N and Ca denote the
reference trajectories used in the simulation. The various colored curves
display the closed loop state responses for the set of 228 aseptic patients, of
which 172 were cured. Note that the measurements N and Ca were corrupted
with Gaussian noise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
xiv
7.9 Time evolution of the control up and ua for the set of 228 aseptic patients
when the measurements N and Ca were corrupted with Gaussian noise. The
zoomed plot for up provides more details on the duration of the control dose,
the x-axis is shown for two hours only since it is zero for the remaining time 110
7.10 Upper part: state trajectories together with corresponding control doses.
Lower: Nonlinear part NL1 and NL2 together with their approximation given
by F1 and F2 respectively . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
7.11 Left: Estimation error of F1 − F1,est. Right: Estimation error of F2 − F2,est . 113
xv
Chapter 1
Introduction
This thesis tackles the problem of controlling a highly nonlinear inflammatory immune
response model, given by a set of differential equations. Given that all variables are not
measurable and the fact that the parameters changes from one patient model to another,
it has been interesting to explore estimation and parameter identification for the objective
of obtaining a better control algorithms able to cope with the lack of information that is
inherent in most real biological processes. We examine the state estimation problem using
well known nonlinear filter techniques and compare the results. For parameter estimation a
recently introduced approximate Markov chain Monte Carlo approach known as the Particle
Metropolis-Hastings will be used. From a control perspective, back-stepping control is
investigated together with its limitation with respect to the inflammatory immune model
of interest. In order to cope with this limitation, optimization approaches seemed to be
a natural choice in this case. Therefore, deriving the optimal doses for treating acute
inflammation is explored using optimal control theory when the objective is linear and when it
is quadratic in the control. Because the proposed parameter and state estimation techniques
usually rely on an accurate model, we decided to focus on another route that employs a
new model-free control framework and its corresponding ”intelligent” controllers. The latter
approach does not use the differential equations representing the process of inflammation,
instead it attempts to offer a better alternative to the well known established model based
control paradigm.
1
1.1 Motivation
The immune response is a complex mechanism triggered in an organism as a result of
biological or physical stress, such as the presence of a foreign body (pathogenic infection)
or trauma. The natural behavior of an organism to respond to these phenomena is through
stress adaptation by trying to eliminate the invading pathogen threat in case of an infection
while also promoting tissue repair due to the self-harming effects of inflammation. However,
an excessive and dysregulated inflammatory response may lead to systemic inflammatory
response syndrome (SIRS) and sepsis, resulting in tissue damage, organ dysfunction or even
death. According to [22], the overall mortality is approximately 30%, rising to 40% in the
elderly and is 50% or greater in patients with severe SIRS and sepsis.
With the withdrawal of previously approved drugs to treat sepsis ([40]) and the
acknowledgment that potential therapies for sepsis such as anti-tumor necrosis factor-α
appear to require accurate timing ([42], [79]), identifying effective therapies and patient-
specific protocols for curbing sepsis is increasingly important. Using computational tools and
methodologies is one means by which to explore this and offer insight. In particular, applying
automatic control for biomedical therapeutic intervention has recently gained interest in
such areas as glucose control for diabetes or in critically ill patients and for anesthesia depth
control, as seen for example, in [72], [17], [31], [44], and the references therein. The obtained
results using the proposed control approaches presented in this thesis, could provide insight
for possible treatment strategies and the methods could be a relevant tool for future practice
to assist in better prediction of clinical outcomes and subsequently better treatment for
patients.
1.2 Background and Overview
Finding a suitable control strategy for the reduced inflammatory immune model [81] led
us in this research project to approach the problem from different perspectives; Control,
state estimation, and parameter identification. The following subsections will provide a brief
overview on these vast areas.
2
1.2.1 State and Parameter Estimation
The theory of filtering and observers originated in the early work of Kalman and Luenberger
more than half a century ago. Although it received great success, its extension to nonlinear
systems is not straightforward and did not receive the same enthusiasm. Many contributions
to expand the nice properties of the Kalman filter to nonlinear system can be found in the
literature and are mainly classified in two main paradigms:
• statistical, mainly based on Bayesian approaches. ([89, 6])
• algebraic type ([93] and references therein )
For the part of statistical method one can mention the Kalman filter itself and all its
extension (e.g., EKF, UKF, iterated EKF (IEKF), Kalman smoother, . . . ) together with
particle filter (PF) methods. To better deal with nonlinear systems, the extended Kalman
filter was suggested by Stanley F. Schmidt after Kalman’s visit [16] . The linearization of
the system should be around the current estimate, rather than the nominal trajectory as
presented by the linearized Kalman filter. The EKF was widely used; however, because of
its poor performance in the presence of severe nonlinearities, due mainly to the fact that it
relies on an approximation (linearization) of the model to propagate the mean and variance,
further research was needed. In the UKF [51, 52, 89] , the same intuition found in a practical
implementation of the particle filter is used, in that, it is easier to perform a nonlinear
transformation on a point rather than an entire probability density function (pdf) [92], and
also we can find points in the state space that represent the pdf well enough such that the
resulting mean and covariance can be propagated with less error. Particle filtering methods
([41, 30]) have become an appealing class of algorithms to solve estimation problems in an
online and recursive way as observations become available. They were first applied in the area
of signal processing [41] and belong to the class of sequential Monte Carlo methods [94]. They
are based on the idea of approximating the target distributions (pθ(xt|y1:t)) sequentially by
sets of weighted samples {xit, wit}Ni=1, known as (weighted) particles. Unlike the UKF where
we approximate the distribution with a mean and a covariance, PF tries to estimates the
whole target distribution. Particle filters and particle smoothers are the main tools when
trying to apply expectation maximization for parameter estimation to a nonlinear system.
3
Maximum likelihood (ML) estimation techniques still remain challenging, especially with
highly nonlinear models.[65, 66]. For the parameter identification part, we investigate the
particle Metropolis-Hastings (PMH, [1]) algorithm. The later provide a framework to allow
one to sample from the sought posterior distribution and ultimately create an empirical
approximation. One would have probably guessed from the term particle in PMH that
particle filter will be a substantial ingredient in the PMH algorithm since it will essentially
approximate the analytically intractable problem of Bayesian inference of nonlinear state
space models.
Algebraic (state or parameter) estimation approaches do not consider the probabilistic
features of the noise to be important. As mentioned in [93], they are not based on asymptotic
approaches, and do not require a probabilistic setting. Sliding mode observers and higher
order sliding mode observers can also be seen to belong to this category [91].
1.2.2 Optimal Control
Optimal control theory has been widely used in biomedical applications, see [95], [54], and
[96] for example; and, more recently, the use of model predictive control (MPC) in [24]
and [108] which used the same mathematical model as used herein. MPC was also used
in [71] and [43] for diabetes treatment strategies and [64] for an application to a multi-
compartment respiratory system. In the cases where MPC is used, an optimal control
problem is essentially solved for each specified time interval over the duration of the time
span, as though implementing the control measures in real time (i.e., online) as the response is
evolving. In this work, we investigate the offline strategy that solves the control problem for
the entire time period of interest: from the start of treatment till the end of the observation
period. Within this strategy, we explore differences in the form of the objective function
used as well as determine the effectiveness of the identified treatment protocol.
In this thesis, we explore the use of optimal control theory to derive an immune control
strategy for the chosen model consisting of manipulating the pro- and/or anti-inflammatory
mediator in order to reestablish the healthy equilibrium of the virtual patient. Note that
the model does not target a specific pathogen and the control doses represent concentrations
of inflammatory mediators with idealized effect on the system. Even so, the careful balance
4
required for effective treatment is evident. For instance, a large dose of pro-inflammatory
therapy, while aiming to eliminate the pathogen, would also pose a risk in causing possibly
irreparable damage to organs. Similarly, using a large amount of anti-inflammatory
therapy could suppress the negative effects of the inflammatory-damage feedback loop
and consequently preserve organ health; however, this intervention may also suppress the
positive effects of inflammation in controlling pathogen which may then be uninhibited to
rapidly grow. The dual objectives to eliminate pathogen but also minimize damage via the
administration of pro- and anti-inflammatory mediators, respectively, necessitates the use of
a control algorithm in order to find a suitable balance that produces the desired outcome: a
healthy patient.
In [9] and [8] the necessary conditions of Pontryagin’s maximum principle [76] were
used in order to formulate a two point boundary value problem (TPBVP) which was
solved numerically with the forward-backward sweep method [63] (indirect method). In
the current work, we choose to use a direct approach to the numerical solutions that relies
on approximating the original optimal control problem by first discretizing the state and
control history and then solving it using nonlinear programming (NL). Further details about
the solver used will be given in section 6.2.3. Constraints are handled more easily in the
direct method than in the indirect method where one must derive adjoint equations along
with the transversality and optimality conditions before the TPBVP problem can be solved.
Furthermore, in the indirect method, the presence of state inequality constraints requires
a priori knowledge of the number and duration of constrained arcs which is unknown
beforehand [20].
We compare the results of using a quadratic or L2 objective function versus a linear or
L1 one. The use of a quadratic cost to derive the optimal control can be explained by two
important facts. First the corresponding Hamiltonian will be strictly convex in the control
with a unique minimum, and second, the mathematical problem is more straightforward
to solve. Alternatively, using an L1 or linear objective avoids distortion due to the square
used in the L2 form which puts a small penalty on lower doses and therefore, potentially
biases the real effect of the control in the cost function [62]. Also, the use of an L1 objective
often results in “bang-bang” controls, meaning the control is applied at either its maximum
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level or its minimum level, which provide simple dosing protocols whose amounts do not
vary greatly over time. In this respect, such controls are more analogous to how medical
treatments are administered in practice and are considered natural choices as candidates for
optimality [99].
The simulation results presented herein show some similarities when compared to [9] and
[8], in that the optimal control doses follow a certain strategy whether considering a quadratic
or a linear objective. As will be noted later, the optimal inputs for a virtual patient whose
inflammatory mediators are elevated above some prescribed threshold are characterized
by a bolus of pro-inflammatory therapy followed just after by anti-inflammatory therapy,
consistent with earlier findings in [24].
1.2.3 Model Free Control
There has been much research focused on the derivation and analysis of various mathematical
models where differential equations play a prominent role (see, e.g., [2, 3, 4, 12, 23, 26, 25,
28, 32, 33, 73, 77, 80]). The usefulness of those equations for simulation, prediction purposes,
and, more generally, for understanding the intimate mechanisms is indisputable. In addition,
some models have also been used in order to provide a real-time feedback control synthesis
(see, e.g., [5] for an excellent introduction to this important engineering topic). Insightful
results were obtained via two main model-based approaches:
• optimal control [8, 9, 10, 54, 95, 97, 96, 101],
• model predictive control [24, 46, 108].
The most recent ones [8, 9, 24, 108] employ a low dimensional system of ordinary differential
equations derived in [80] (see also [25]). It possesses the following characteristics:
• The model is based on first principles regarding the non-specific protective mechanisms
of the innate immune response to infection.
• A variable that represents anti-inflammatory mediators is included: they play an
important role in mitigating the negative effects of inflammation in order to avoid
tissue damage and high pathogen proliferation.
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• Though a qualitative model of acute inflammation, it reproduces several clinically
relevant outcomes from healthy resolution to death outcomes.
The calibration of a modeling via differential equations might be quite difficult, i.e., the
identification of the necessary parameters necessitate the acquisition of data, which might
be tedious if not impossible. Let us emphasize moreover the huge heterogeneity between
patient responses such as the initiating circumstances, patient co-morbidities and personal
characteristics, like genetics, age, gender, . . . . In spite of promising preliminary results [7, 11,
108], state estimation and parameter identification for those highly nonlinear equations may
still be beyond our theoretical understanding. Those roadblocks hamper the use of model-
based control strategies in clinical practice in spite of recent mathematical advances. Here,
another route, i.e, model-free control (MFC ) and the corresponding “intelligent” feedback
controllers [103], is therefore explored.1 An introduction to this promising control approach
together with an application to the inflammatory immune model will be give in chapter 7.
1.3 Summary of Contributions
The contribution of this work is summarized as follows:
• The research starts with an analysis of nonlinear observability, and successfully
shows the system is locally observable. Then different well known nonlinear filtering
techniques are explored and compared. It is shown that particle filtering is more
efficient and less sensitive to noise when compared to the extended Kalman and
unscented Kalman filters. The parameter identifiability of the immune model is also
verified.
• An approximate particle Markov chain Monte Carlo (MCMC) known as the Particle
Metropolis-Hastings (PMH) will be shown to be efficient in estimating the parameter
of the inflammatory immune model.
1This new viewpoint in control engineering has been successfully illustrated in many concrete case-studies
(see, e.g., the references in [103], and [50, 61, 69, 70, 82, 27, 85, 102, 105]). Some of them have been patented.
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• The nonlinear controllability of the immune model was verified around different
equilibria. The research is followed up by the derivation of the optimal controller, when
considering either a quadratic or a linear objective. The resulting control strategies
were in both cases able to stabilize the virtual patient to his/her healthy state. An
important finding with L1 objective is that successful therapies for different initial
conditions and virtual patients have been identified, and consist in providing a pro-
inflammatory dose for a small period of time followed by a longer application of an
anti-inflammatory dose. As a consequence of lowering the intensity of the dose the
optimal control compensate by allowing to have a longer application. The result can
provide insight in better treatments of pathogenic infection or stress.
• Recently, we explored another route that employs a new model-free control and its
corresponding ”intelligent” controllers to an inflammatory response model. A most
interesting feature of the proposed control design is the fact that the two outputs
which must be driven are sensorless. This difficulty is overcome by assigning suitable
reference trajectories to two other outputs with sensors. The obtained results are very
promising in two respects:
– The approach does not make use of the model to design the controller. The
modeling remains nevertheless irreplaceable at this stage for in slilico testing.
– The generated control dosage confirm the pattern already observed when com-
pared to the results obtained with optimal control.
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1.4 Thesis Organisation
This proposal is organised as follows:
Chapter 2 introduces the mathematical model of the inflammatory innate immune response,
that will be used in this work.
In chapter 3 criteria for evaluating the nonlinear controllability, observability together with
the identifiability of the immune model are discussed..
In Chapter 4 various nonlinear filter approaches will be briefly introduced, including the
extended Kalman filter (EKF), the unscented Kalman filter (UKF), and the particle filter
(PF). A comparison of these nonlinear filters is presented and their performance is evaluated
in terms of accuracy and consistency.
Chapter 5 provide an introduction to the particle Metropolis-Hastings for the purpose of
estimating the unknown parameters of the inflammatory immune model. Simulation results
of the parameter posterior distribution is provided together with the autocorrelation function
of the Markov chain.
Chapter 6 explores mainly two different ways of solving the control problem. A model
based control employing optimal control theory with the help of Pontryagin minimum
principle to derive the control solution. Another new model free approach will also be
discussed.
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Chapter 2
Mathematical model
2.1 A virtual patient
In this thesis, we utilize a phenomenological ordinary differential equations model of the
inflammatory response to pathogenic infection developed in [81] (see also [25]). This model
provides a dynamical system with rich behavior that is ideal for testing various theoretical
control strategies. A summary of its important features are as follows:
• This model is based on the early non-specific protective mechanism, namely, the innate
immune response, in contrast to the mechanisms of adaptive immunity. It is a lumped
variable/lumped parameter model, representing an abstract view of the dynamics of an
acute inflammatory response and implicitly considering affects of typical intervention
strategies such as antibiotic use or the administration of resuscitating fluids;
• An anti-inflammatory mediator is included as a dynamic variable of the model. This
mediator plays an important role in directly mitigating inflammation as a way to
prevent excessive tissue damage caused by severe inflammation; and
• The model’s biological relevance has been confirmed through its good qualitative
reproduction of severe systemic inflammatory states as observed in a clinical setting.
One can think of the model as representing the immune dynamics of a virtual patient. There
are four system states of the model:
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• P : the bacterial pathogen population that initiates the inflammatory response;
• N : combined collection of early pro-inflammatory mediators such as activated
phagocytes (e.g. neutrophils) and the pro-inflammatory cytokines they produce;
• D : a marker of global tissue damage which incites further inflammation and which is
useful for determining response outcomes; and
• Ca: combined collection of anti-inflammatory mediators, such as cortisol, Interleukin-
10 (IL-10) and Transforming Growth Factor-beta (TGF-β).
In [24] it was first proposed to include non-negative, time-varying inputs to account for
therapeutic controls in this model. Here, we denote these as follows:
• up(t): a pro-inflammatory enhancer that provides direct input into the N equation;
and
• ua(t): an anti-inflammatory enhancer that provides direct input into the Ca equation.
The dynamic equations describing the interactions of the four system variables, P , N ,
D, and Ca, are governed by various rate constants or parameters whose numerical values
can be found in [81]. As was done in [24], we consider different sets of parameter values to
represent different virtual patients’ inflammatory responses. We refer to the values given in
[81] as the reference set of parameter values.
The diagram in Figure 2.1 characterizes the different interactions that exist between the
states of the inflammatory model. A solid line with an arrow head indicates an up-regulation,
whereas a dashed line with circular head indicates inhibition or downregulation of a process.
For instance, early pro-inflammatory mediators, N , respond to the presence of pathogen,
P , by initiating self-recruitment of additional inflammatory mediators and N is therefore
upregulated by the interaction with P to attempt to efficiently eliminate the pathogen.
The self up-regulation that exists for P is due to replication. Furthermore, N suppresses
P by eliminating it at some rate when they interact; however, the inflammation caused
by N results in tissue damage, D, which can provide a positive feedback into the early
inflammatory mediators depending on their intensity. To balance this, anti-inflammatory
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Figure 2.1: Diagram of natural and enhanced immune dynamics in response to pathogenic
stimulus. P : replicating pathogen, N : early pro-inflammatory immune mediators, D:
marker of tissue damage/dysfunction caused by inflammatory response, Ca: inhibitory anti-
inflammatory mediators, ua and up: time-varying input controls for the anti- and pro-
inflammatory therapy, respectively. Solid lines with arrow heads and dashed lines with
nodes/circular heads represent upregulation and inhibition, respectively.
mediators (e.g., cortisol, IL-10, TGF-β) can mitigate the inflammation and its harmful
effect by suppressing the response by N and the effects of D in various ways. The ordinary
differential equations modeling these interactions is given by Equations (2.1) - (2.4):
P˙ (t) = kpgP (t)
(
1− P (t)
p∞
)
− kpmsmP (t)
μm + kmpP (t)
− kpnF (N(t))P (t) (2.1)
N˙(t) =
snrR(P (t), N(t), D(t))
μnr +R(P (t), N(t), D(t))
− μnN(t) + up(t) (2.2)
D˙(t) = kdn
F (N(t))6
x6dn + F (N(t))
6
− μdD(t) (2.3)
C˙a(t) = sc + kcn
F (N(t) + kcndD(t))
1 + F (N(t) + kcndD(t))
− μcCa(t) + ua(t), (2.4)
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where
R(P,N,D) = F (knpP (t) + knnN(t) + kndD(t)) and
F (x) =
x
1 +
(
Ca(t)
c∞
)2 .
At the end of 168 hours, a healthy outcome of a virtual patient’s inflammatory response
given a particular initial pathogen is defined as the ending state in which D = 0, P = 0,
N = 0, and Ca is at its initial background level. On the other hand, a patient is considered to
have an unhealthy outcome if the ending state has either P = 0 with all other variable values
elevated above their background non-infection steady state values (aseptic death outcome)
or when P is also elevated along with the other variables (septic death outcome). The
fact that a virtual patient may, or may not, return to a healthy state depends on the
parameter values and initial condition. When inflammatory levels of a response are deemed
excessive (i.e. N(t) > 0.5 in this work), then intervention becomes necessary to stabilize
the patient to its healthy equilibrium (i.e. to homeostasis). In the work here, we consider
two virtual patients whose inflammatory response outcomes are septic death and aseptic
death, respectively, in the absence of intervention measures. Below, we summarize for each
virtual patient the corresponding parameter values used as well as the initial conditions
which represents the state of the patient’s inflammatory response some time past when the
initial infection occurred, when the inflammatory response has become elevated enough to
warrant therapeutic intervention.
1. Patient 1 (septic death outcome)
• Initial conditions: P (0) = 0.5360, N(0) = 0.0660, D(0) = 0.0477, Ca(0) = 0.1635.
• Parameter values differing from reference set: kpg = 0.5846, kcn = 0.0409, knd =
0.0242, knp = 0.1211, kcnd = 49.1243, knn = 0.012.
2. Patient 2 (aseptic death outcome)
• Initial conditions: P (0) = 1.0017, N(0) = 0.0711, D(0) = 0.0732, Ca(0) = 0.1314.
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Figure 2.2: Time courses of system states for natural (open loop) response for virtual
patient 1 (solid curves), resulting in a (septic death outcome) and for virtual patient 2
(dashed curves), resulting in an (aseptic death outcome.)
• Parameter values differing from reference set: kpg = 0.4746, kcn = 0.0386, knd =
0.0223, knp = 0.1116, kcnd = 46.3367, knn = 0.0112.
The differential equations model using the parameter values and initial conditions corre-
sponding to each virtual patient is numerically solved and the resulting time courses for
each are shown in Figure 2.2. Solid curves display the solution time courses for patient 1
and dashed curves are for patient 2. As illustrated, in the absence of any control measures,
each virtual patient’s trajectory evolves toward either of the final unhealthy steady states.
Next, we demonstrate how interventions via positive inputs into the system can redirect
trajectories away from the unhealthy steady states and toward the healthy steady state.
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Chapter 3
Nonlinear Controllability and
Observability
In this chapter we present the elementary tools and definitions of the theory of nonlinear
controllability and observability from a differential-geometric approach. What follows was
summarized from the work of Hermann and Krenner [45], Krener [59] and Isidori [47].
Note that nonlinear observability is related to the notion of Lie derivative, while nonlinear
controllability is tied to the notion of Lie bracket. The first represent the derivative of a
scalar function along a vector field, while the second can be thought of as the derivative of
a vector field with respect to another.
3.1 Introduction
Throughout this proposal we will consider the previously introduced inflammatory immune
model. The latter is affine in the control and can be written as:
Σ
⎧⎪⎨
⎪⎩
x˙ = f(x(t),u(t)) = f(x) + g1(x)up(t) + g2(x)ua(t)
y = h(x(t)), x(0) = x0
(3.1)
where f(x) is a vector valued function such that f(x) : R4 → R4, and x ∈ R4. y :
R
4 → R2, gi ∈ R4 and u : R → R2. g1 = [0, 1, 0, 0]T , g2 = [0, 0, 0, 1]T . The vector f(x)
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is obvious from the model equations. We also assume the system is complete, i.e, for every
bounded measurable input u(t) and every initial condition x0 ∈ M there exists a solution to
x˙ = f(x(t), u(t) for ∀t ∈ R and x(t) ∈ M .
3.2 Nonlinear Controllability
In general, we say a system is controllable if there exist a measurable control function t → u(t)
that drives any initial state x0 to another desired state x1 in a finite time.
3.2.1 Controllability Rank Condition:
We say that a system Σ satisfies the controllability rank condition at x0 if in a neighborhood
M of x0, dim < adf |R(f) > (x) = n [47]. If this holds for each x0 ∈ M , we say that Σ
satisfies the controllability rank condition.
The above condition can be verified by showing that the vector fields {g, adfg, ...,
adn−1f g} are linearly independent in M and the set {g, adfg, ..., adn−2f g} is involutive.
Involutivity means that if one forms the lie bracket of any pairs of a vector fields from
a given set, then the resulting vector field can be expressed as a linear combination of the
original set of vector fields. The controllability matrix is found by calculating the Lie bracket
of the pair f and g up to order n − 1. Since gi for i = 1, 2 are constant in our case, they
consequently are involutive.
Definition 1: Let f and g be two vector fields on Rn. The Lie bracket of f and g is a
third vector field defined by
[f ,g] = adfg = ∇g f −∇f g (3.2)
Repeated Lie brackets can be defined recursively by
ad0f g = g (3.3)
adif g = [f , ad
i−1
f g] for i = 1, 2, ... (3.4)
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Example 3.1. Consider the following linear system x˙ = Ax + Bu, M = Rn with
f(x) = Ax gi(x) = Bi. The Lie bracket of each term will be given according to
[Ax,Bi] = −ABi, [Ax, [Ax,Bi]] = −A2Bi, . . . , therefore if we consider
R(f)(x) = span{Ax,B1, . . . , Bm}. then the controllability distribution is given by
< adf |R(f) >= span{B1, . . . , Bm, AB1, . . . , ABm, . . . , An−1B1, . . . , An−1Bm}
Using the previous theory we can see the rank condition applied to an affine linear
system, is equivalent to the Kalman controllability rank condition, i.e., < adf |R(f) >=
rank{B,AB, . . . , An−1B} = n
It is now, easy to see how nonlinear controllability condition can be verified by making
sure the rank of the following matrix is n = 4.
η = {g1,g2, [f ,g1], [f ,g2], [f , [f ,g1]], [f , [f ,g2]], ...} (3.5)
Applied to our model, the first two Lie bracket derivatives are given as follow:
Fg1 = [f ,g1] = −∇f g1 (3.6)
Fg2 = [f ,g2] = −∇f g2 (3.7)
FFg1 = [f ,Fg1] = ∇Fg1.f −∇f .∇Fg1 (3.8)
FFg2 = [f ,Fg2] = ∇Fg2.f −∇f .∇Fg2 (3.9)
Where Fg1, Fg2, FFg1, FFg2 are vector valued functions. Note that we offer a comple-
mentary analysis of local controllability of the one presented in [108]. We can verify using
the previous matrix that the system is locally controllable around the healthy equilibrium [0,
0, 0, 0.125]. If we chose an initial state given by [P N D Ca] = [0.1 0.01 0.01 0.02],
then using maple we obtain the following full rank matrix.
It is not as much emphasized in the literature when treating controllability to talk about
stabilizability. The latter notion is very important as will be shown shortly. First, note the
matrix η is positive definite for P , N , D, Ca > 0. it loses rank if P = 0, N , D, Ca > 0.
This however does not mean that the system is not controllable, since the state P that loses
the controllability feature is stable. It can be seen that linearization around P = 0, result
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in a stable ODE equation that only depends on P . If for example N = 0, with the rest
of the state positive, then we also lose rank. Again, one can easily check Equation 2.3 and
conclude about the stabilizability of the system. The controllability matrix will not lose rank
for having the state D = 0. The solution of the differential equation result in a trajectory
that increases, however will be stabilizable because of the term −μdD. A combination of
any zero state would result in a similar argument. One also can reach the same conclusion
for the other two steady state points, which are calculated given the parameter set of the
reference model as follows:
[0, 0.635, 17.399, 0.5229], [2.744, 0.864, 17.48, 0.522], for aseptic and septic state respectively.
We summarize by saying the immune system treated in this proposal is locally controllable
at all equilibrium points. It is important to see the notion of controllability found in the
literature, does not take into account the constrained control nor the region of the state space
we are concerned with, consequently in the simulations if one is unable to control a state
to a desired point, it is crucial to remove the constraints, just to make sure controllability
holds.
3.3 Nonlinear Observability
In this section we introduce an important concept related to the observability of nonlinear
system that will serve as a support for using nonlinear state estimation algorithms. Herman
and Krener [45] associated observability to the idea of distinguishability of states with respect
to the inputs. Two states are called U-distinguishable if there exist a bounded measurable
input u(t), t∈ [0 T] such that both state trajectory remain in U and each one of them
generate different output.
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Definition 3.2. [48] Two states x0 and x1 in M are U-distinguishable if there exists a
bounded measurable control t → u(t), defined on some interval [0, T ] that generates solutions
x0(t) and x1(t) satisfying xi(0) = xi such that xi(t) ∈ U for all t ∈ [0, T ] and the measured
outputs y = h(x0(t)) = h(x1(t)) for some t ∈ [0, T ]. Denote by I(x0, U) the set of all points
x1 that are not U-distinguishable from x0.
Notice that local observability implies local distinguishability as we can set V = M .
Therefore, if a system does not have the local distinguishability property at some point x0
it is not locally observable at that point either. The next section formalize the previous
definition into a test.
3.3.1 Observability Rank Condition
Local distinguishability property is determined by using the so-called observability rank
condition [47] [45].
Theorem 3.3. The system Σ has local distinguishability property for all x in an open set M
if and only if dim dG = n, where
dG = span{dLfhj, dLgjhj, dLifhj, . . . , dLigjhj} (3.10)
Where i = 1, . . . , n− 1, and j = 1, . . . , p.
To understand the previous theorem, lets introduce the notion of Lie derivative
Definition 3.4. The Lie derivative of a C∞ scalar function h on an open subset S ⊂ Rdim(X)
along an analytic vector field f on S, is defined as the scalar function given by:
Lfh = dhf, (3.11)
where dh is the gradient of h.
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Repeated Lie derivatives can be defined recursively as
L0fh = h (3.12)
Lifh = Lf (L
i−1
f h) for i = 1, 2, . . . (3.13)
Given the measurements N and Ca we define the vector y as follow z = [h1 h2]
T = [N Ca]
T
The following represent the span of all Lie derivatives of h1 and h2 both with respect to f, g1
and g2 up to order n− 1.
G = span{Lfh1, Lfh2, Lg1h1, Lg1h2, Lg2h1, Lg2h2, ..., L3g2h2}.
Where g1, g2, f(x) are the vector function defined previously. The observability matrix is
defined below as the space spanned by the gradiant of G
dG = span
{
⎡
⎢⎢⎢⎢⎢⎢⎣
∂
∂P
L0f,g(h1)
∂
∂P
L1f,g(h1) . . .
∂
∂P
L3f,g(h2)
∂
∂N
L0f,g(h1)
∂
∂N
L1f,g(h2) . . .
∂
∂N
L3f,g(h2)
∂
∂D
L0f,g(h1)
∂
∂D
L1f,g(h1) . . .
∂
∂D
L3f,g(h2)
∂
∂Ca
L0f,g(h1)
∂
∂Ca
L1f,g(h1) . . .
∂
∂Ca
L3f,g(h2)
⎤
⎥⎥⎥⎥⎥⎥⎦
}
(3.14)
The first order Lie derivatives for our system are
Lfh1 = dx2f = [0, 1, 0, 0].[f1, f2, f3, f4]
T = f2
Lfh2 = dx4f = [0, 0, 0, 1].[f1, f2, f3, f4]
T = f4
Lg1h1 = 1
Lg1h2 = 0
Lg2h1 = 0
Lg2h2 = 1
It is easy to proceed with higher order derivatives. Since the gradient of the constants will
give 0, we follow with the second order Lie derivative. That is, we continue the derivatives
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using Lfh1 and Lfh2. i.e., Lg1Lfh1, Lg1Lfh2, Lg2Lfh1, Lg2Lfh2 The Observability matrix is
defined below as the space dG spanned by the gradients of G
dG = span{g1, g2, dLfh1, dLfh2, dLg1h1, dLg1h2, dLg2h1, dLg2h2}
Using Maple, it has been sufficient to calculate the Lie derivative up to order 2 to show
that the matrix dG has full rank: i.e rank 4. Note that this was computed on the model
using a reference set of parameter values given in Table 4.2. and at the healthy state, i.e.,
([P,N,D,Ca] = [0, 0, 0, 0.125]).
The notion of observability for nonlinear system can be understood from a local
perspective. however we can always check points in the state space that are of interest
as it has been done. If we can find one initial state such that the above condition is not
satisfied then it is enough to say that the system is not observable.
3.4 Parameter identifiability
In this section we will see that by considering parameters as states with time derivative zero,
it is possible to use the previous observability rank test to determine identifiability. The
problem of parameter identifiability (inverse problem) as of the observability of nonlinear
system is important, since it is necessary to know precisely the structure of the model
to implement any model-based controller. One needs to know that given a certain set
of measurements y1:T and controls u1:T (input-output behavior) and their associated time
derivative, if it is possible to uniquely infer the value of the unknown parameters (locally for
the case of nonlinear system 1). In [75] the author used the coefficients of a Taylor series
1 Global identifiability considers the issue of uniquely estimating all the free parameters of a model from
available input/output data [67]. Note that it is possible to study the global identifiability of a nonlinear
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expansion of the output to determine the parameter identifiability of a class of nonlinear
system applied in pharmaco-kinetic studies. The paper [106] propose the study of different
ideas for nonlinear identifiability from an algebraic framework, they also offer solutions to
what needs to be measured in case the actual measurements are not enough for identifiability
purpose and what is the best time to take such measurements.
3.4.1 Identifiability rank condition
Now we will see how the observability rank condition can be used to determine parameter
identifiability. Consider the following ODE defined according to
Σ
⎧⎪⎨
⎪⎩
x˙ = f(x, θ, u)
y = h(x, θ),
(3.15)
x ∈ R4 and u : R → R2 are the state and control vector respectively. y : R4 → R2 is
the measurement vector. The k model parameters are denoted by θ. f and h are vectors of
analytical functions. In order to use the idea of previous section, we observe that the above
differential equations can be expressed as
Σ
⎧⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎩
θ˙ = 0
x˙ = f(x, θ, u)
y = h(x, θ),
(3.16)
where θ can be considered as a state variable. The rank test for observability can therefore
be applied in a similar fashion. The initial condition for the state vector is selected to
be [P,N,D,Ca] = [0.2, 0.02, 0.5, 0.01]. The problem of state observability is not an issue
anymore, we focus our attention on the identifiability problem. i.e., is the set that generated
the input/output map unique? (at least locally). The rank condition can provide a good
system if the solution of the system of equation generated from the computation of the successive Lie
derivative of f and g is unique
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answer. That is, consider the following Jacobian matrix:
dG = span
{
⎡
⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
∂
∂θ1
L0f,g(h1)
∂
∂θ1
L1f,g(h1) . . .
∂
∂θ1
L3f,g(h2)
∂
∂θ2
L0f,g(h1)
∂
∂θ2
L1f,g(h2) . . .
∂
∂θ2
L3f,g(h2)
∂
∂θ3
L0f,g(h1)
∂
∂θ3
L1f,g(h1) . . .
∂
∂θ3
L3f,g(h2)
∂
∂θ4
L0f,g(h1)
∂
∂θ4
L1f,g(h1) . . .
∂
∂θ4
L3f,g(h2)
∂
∂θ5
L0f,g(h1)
∂
∂θ4
L1f,g(h1) . . .
∂
∂θ5
L3f,g(h2)
∂
∂θ6
L0f,g(h1)
∂
∂θ4
L1f,g(h1) . . .
∂
∂θ6
L3f,g(h2)
⎤
⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
}
(3.17)
where [θ1, θ2, θ3, θ4, θ5, θ6] = [kpg, kcn, knd, knp, kkcnd, knn] are the unknown parameters in our
inflammatory immune model. We similarly use Maple for its efficiency in handling symbolic
computation. It has been observed that the rank of the observability condition was equal
to 6 when the initial state [P,N,D,Ca] = [0.2, 0.02, 0.5, 0.01] is chosen. Other initial state
around the equilibrium have been selected and it was observed that the rank condition is
preserved. We conclude by saying that the inflammatory immune model is at least locally
identifiable. We will see in chapter 5 that it is in fact possible to have a relatively good
estimate of the unknown parameters using an approximate version of the Markov chain
Monte carlo approach that can be used for nonlinear system.
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Chapter 4
Nonlinear State Estimation
The inflammatory response is a complex, highly nonlinear biological process, for which
complete measurements of all variables are not usually available. Since it is desirable to find
therapeutic inputs that enable the response to be controlled toward a favorable outcome,
it is crucial to estimate the states that are impossible to measure, and use them for the
appropriate control strategy. Various state estimation approaches will be briefly introduced,
including the extended Kalman filter (EKF), the unscented Kalman filter (UKF), and the
particle filter (PF) [7]. A comparison of these techniques is presented with respect to the
reduced model of inflammation and the performance of each filter is evaluated in terms of
accuracy and consistency.
4.1 Introduction
It is important to know how to define any estimation problem. The probability density
function p(xt|y1:t) contains all statistical information available about the state variable xt,
based on the information in the measurements y1:t [49], where:
y1:t = {y1, y2, . . . , yt} = Yt (4.1)
The filtering problem is considered solved when we are able somehow to approximate the
filtering density p(xt|y1:t). Based on this approximation we can deduce various state estimates
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[30] :
I(g(xt))  Ep(xt|y1:t){g(xt)} =
∫
Rnx
g(xt)p(xt|y1:t)dxt (4.2)
where g(xt) = xt gives an estimate of the approximated density.
Dynamical models in general are given using a state space formulation:
xt+1 = ft(xt, vt, θ) (4.3)
yt = ht(xt, et, θ) (4.4)
Where xt ∈ Rnx denotes the state, yt ∈ Rny denotes the measurement, θ ∈ Rnθ denotes the
parameter vector, unknown when considering parameter identification. vt and et represent
the process and measurement noise respectively. The process function is given by ft : R
nx ×
R
nv → Rnx and the function modeling the sensors is denoted by ht : Rnx × Rne → Rny . For
both sections of this chapter a nonlinear discrete-time state space model with additive noise
is considered
xt+1 = ft(xt) + vt vt ∼ N (0, Qt) (4.5)
yt = ht(xt) + et et ∼ N (0, Rt) (4.6)
With vt and et independent and identically distributed (i.i.d)
4.2 The extended Kalman filter (EKF)
The extended Kalman filter (EKF) is just an extension of the basic Kalman filter applied
to a linearized model [15, 16]. The Kalman Filter estimates, in this case, can be used
as the nominal trajectory. Linearizing the nonlinear system around the Kalman filter
estimate instead of the sate trajectory is the basic idea of the Extended Kalman filter.
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More specifically consider the first-order Taylor expansion around the current estimate,
f(xt, t) ≈ f(xˆt|t, t) + ∂f(x, t)
∂x
∣∣∣∣∣
x=xˆt|t
(xt − xˆt|t) (4.7)
h(xt, t) ≈ h(xˆt|t−1, t) + ∂h(x, t)
∂x
∣∣∣∣∣
x=xˆt|t−1
(xt − xˆt|t) (4.8)
Now that the nonlinear model is approximated by a linear, Gaussian model in xt, Kalman
filter can be applied to obtain the following algorithm
Algorithm 1 Extended Kalman filter (EKF) [92]
An approximate estimate for the filter density p(xt|Yt) is recursively given by
pˆ(xt|Yt) = N (x; xˆt|t, Pt|t) (4.9)
pˆ(xt+1|Yt) = N (x; xˆt+1|t, Pt+1|t) (4.10)
Where
xˆt|t = xˆt|t−1 +Kt(yt − h(xˆt|t−1, t)) (4.11)
Pt|t = Pt|t−1 −KtHtPt|t−1 (4.12)
xˆt+1|t = f(xˆt|t, t) (4.13)
Pt+1|t = FtPt|tF Tt +Qt (4.14)
Kt = Pt|t−1HTt (HtPt|t−1H
T
t +Rt)
−1 (4.15)
With initial values x1|0 = x¯1 and P1|0 = Π¯. Furthermore, Ft and Ht given by
Ft =
∂f(x, t)
∂x
∣∣∣∣∣
xt=xˆt|t
Ht =
∂h(x, t)
∂x
∣∣∣∣∣
xt=xˆt|t−1
(4.16)
4.3 Unscented Kalman filtler
While the EKF relies on linearization to propagate the mean and the covariance of the state,
the unscented Kalman filter (UKF) [51, 52, 89] uses a set of deterministic vectors called
sigma points whose ensemble mean and covariance are assumed to be initially known.
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Algorithm 2 Unscented Kalman Filter (UKF) [92]
To propagate from time step t to t+ 1, first choose sigma points x˜(i) by starting from the
current best guess for the mean and covariance of xt, xˆt|t and Pt|t:
xˆ
(i)
t−1 = xˆt−1|t + x˜
(i) i = 1, . . . , 2n (4.17)
x˜(i) = (
√
nPt|t)Ti i = 1, . . . , 2n (4.18)
x˜(n+i) = −(√nPt|t)Ti i = 1, . . . , 2n (4.19)
Propagate the sigma points through f first:
xˆ
(i)
t = f(xˆ
(i)
t−1, ut+1) (4.20)
xˆt|t−1 =
1
2n
2n∑
i=1
xˆ
(i)
t ; (4.21)
Estimate the a priori covariance with adding the process noise:
Pt|t−1 =
1
2n
2n∑
i=1
(xˆ
(i)
t − xˆt|t−1)(xˆ(i)t − xˆt|t−1)T +Qt−1; (4.22)
generate another set of sigma point, this time using xˆt|t−1 and Pt|t−1:
xˆ
(i)
t = xˆt + x˜
(i) i = 1, . . . , 2n (4.23)
x˜(i) = (
√
nPt|t)Ti i = 1, . . . , 2n (4.24)
x˜(n+i) = −(√nPt|t)Ti i = 1, . . . , 2n; (4.25)
Update the sigma points using the measurement function:
y
(i)
t = h(xˆ
(i)
t ) (4.26)
yˆt =
1
2n
2n∑
i=1
y
(i)
t (4.27)
Py =
1
2n
2n∑
i=1
(y
(i)
t − yˆt)(y(i)t − yˆt)T +Rt (4.28)
Pxy =
1
2n
2n∑
i=1
(xˆ
(i)
t − xˆt|t−1)(y(i)t − yˆt)T ; (4.29)
Measurement update of the state estimate together with the covariance
Kt = PxyP
−1
y (4.30)
xˆt|t = xˆt|t−1 +Kt(yt − yˆt) (4.31)
Pt|t = Pt|t−1 −KtPyKTt (4.32)
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Propagating these n sigma points through the model’s nonlinear function, generates a
new mean and covariance that are assumed to be closer to the real ones [92], i.e, the nonlinear
functions xˆ
(i)
t = f(xˆ
(i)
t−1) and then y
(i)
t = h(xˆ
(i)
t ) are then applied to each deterministic vector
to obtain transformed vectors. The ensemble mean and covariance will give a good estimate
of the true mean and covariance of y.
4.4 Particle filter (PF)
We will give more attention to the PF since it turns out to be a significant tool to approximate
complicated integrals based on Monte Carlo methodologies, it will be also used in the
parameter identification section. The particle filter offers an approach of solving the nonlinear
filtering problem presented in the introduction, i.e., finding a way to approximate the filtering
density p(xt|y1:t). We will assume the model (4.5)-(4.6) can be expressed in the following
alternative form
xt+1 ∼ p(xt+1|xt) = pvt(xt+1 − ft(xt)) (4.33)
yt ∼ p(yt|xt) = pet(yt − ht(xt)) (4.34)
Where we have used probability density function (pdf) to express both the dynamics and
measurements equation.
Remark 4.1. In what follows, the use of Bayes’ theorem and the Markov property will be
ubiquitous
The filtering density can be expressed as p(xt|y1:t) = p(xt|yt, y1:t−1) = p(xt|yt, Yt−1).
Using Bayes theorem and the Markov property it can be given by
p(xt|y1:t) = p(yt|xt, y1:t−1)p(xt|y1:t−1)
p(yt|y1:t−1) =
p(yt|xt)p(xt|y1:t−1)
p(yt|y1:t−1) (4.35)
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The main densities that remain unknown in the previous expression are p(xt|y1:t−1) and
p(yt|y1:t−1). By using the idea of marginalizing with respect to xt we have
p(yt, xt|y1:t−1) = p(yt|xt)p(xt|y1:t−1) (4.36)
Which will result in
p(yt|y1:t−1) =
∫
p(yt|xt)p(xt|y1:t−1)dxt (4.37)
To derive the one step ahead prediction density p(xt+1|y1:t) we use the same idea.
p(xt+1|y1:t) =
∫
p(xt+1|xt)p(xt|y1:t)dxt (4.38)
Analytical solution of the previous densities are not usually available, since the
multidimensional integrals make the problem intractable. It is interesting however to notice
that if the functions f(.) and h(.) are linear and when the involved stochastic states are
normal together with the noise being additive and independent, then the previous densities
reduces to the known Kalman filter.1 The idea of solving the particle filter is similar to the
UKF, in the fact both algorithms rely on generating a set of particles to approximate the
target density. There are however some major differences in the way both approaches are
performed.
The basic idea of particle filter is to employ random samples generated from their associated
distributions in order to approximate the target density p(xt|Yt). The strong law of large
number (SLLN) is used to justify the validity of the obtained approximation. Let us assume
we can generate samples xi from a target density t(x) such that tˆN(x) =
∑N
i=1w
iδ(x− xi),
now using this empirical density an approximation of I(g(x)) is given
IˆN(g(x)) =
∫
g(x)tN(x)dx =
∫
g(x)
N∑
i=1
wiδ(x− xi)dx =
N∑
i=1
wig(xi) (4.39)
1See, e.g., Chapter 6 in [55] for the derivation
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Where
lim
N→∞
IˆN(g(x))
a.s−→ I(g(x)) (4.40)
What we just presented resumes the main concept behind Monte Carlo methods.
4.4.1 Importance Sampling
Obtaining samples xi directly from a target density t(x) is most of the time not possible.
Importance sampling (IS) uses an approximate distribution called importance density2 q(x)
from which it is easier to draw samples. The previous expectation approximation becomes
I(g(x)) =
∫
g(x)t(x)dx =
∫ [
g(x)
t(x)
q(x)
]
q(x)dx (4.41)
Where the importance density q(x) is required to have at least the same support as t(x).
Since the above expression is just the expectation of the terms in the bracket over the
distribution q(x) a Monte Carlo approximation can be formed by drawing N samples from
the importance density such that this time
xi ∼ q(x), i = 1, . . . , N (4.42)
and the above expectation can be given according to
I(g(x)) ≈ 1
N
N∑
i=1
t(xi)
q(xi)
g(xi) (4.43)
=
N∑
i=1
wˆig(xi) (4.44)
Where the weights are given as
wˆi =
1
N
t(xi)
q(xi)
(4.45)
2It is also known in the literature as the proposal density
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Let’s remember that in the nonlinear filtering problem, the target density is given by
t(x) = p(xt|y1:t). In order to use the IS idea it is necessary to use an appropriate proposal
density q(xt) and a corresponding importance weight. According to Equation 4.35 we can
suggest the following
p(xt|y1:t)︸ ︷︷ ︸
t(xt)
∝ p(yt|xt)︸ ︷︷ ︸
w(xt)
p(xt|y1:t−1)︸ ︷︷ ︸
q(xt)
(4.46)
Let’s start at time t = 0 by initializing the particle and their corresponding weights according
to
xi0 ∼ p(x0) (4.47)
wi0 =
1
N
resulting in (4.48)
pˆN(x0) =
N∑
i=N
1
N
δ(x0 − xi0) (4.49)
Assume at time t that the following approximation is available
pˆN(xt−1|y1:t−1) =
N∑
i=1
1
N
δ(xt−1|xit−1) (4.50)
is available at time t − 1. We are now interested in generating N i.i.d samples {x˜it}Nt=1
from our proposal density q(xt) = p(xt|y1:t−1). By using the expression of the one step ahead
prediction given in Equation 4.38 and the approximation of the previous filtering density
given in Equation 4.50, it is easy to show that
q(xt) = p(xt|y1:t−1) =
N∑
i=1
1
N
p(xt|xit−1) (4.51)
this means that the proposal density can be chosen to be
q(xit) = p(xt|xit−1) (4.52)
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Therefore the predicted particles {x˜it}Ni=1 are obtained simply by propagating {xit−1}Ni=1
through the process dynamics x˜it ∼ p(xt|xit−1) for i = 1, . . . , N . Next we can deduce the
importance weights w˜it = p(yt|x˜it) for i = 1, . . . , N . The acceptance probabilities are given
by normalizing the importance weights
wit =
w˜it∑N
j=1 p(yt|x˜jt)
(4.53)
we have finally derived the approximation of the filtering density given as
p˜N(xt|y1:t) =
N∑
i=1
witδ(xt − x˜it) (4.54)
The main drawback that delayed and prevented practical application of PF is the so
called degeneracy problem. A situation where almost all particles have zero or nearly zero
weights. This problem can be solved by using resampling3 [41]. The idea of resampling is to
eliminate the particles with lower weight values and duplicate the ones with large weights.
It can be described in the following point :
• Each weight wit can be seen as the probability of obtaining the sample index i in the
set {xit : i = 1, . . . , N}.
• Draw N samples from the distribution formed by previous weights and replace the old
sample set with this new one.
• Set all weights to the constant value wjk = 1N .
3See also point 4 in algorithm 3. The equation is just a way to say that the probability of drawing sample
x˜jt is given by the corresponding weight w
j
t or similarly, the larger the weight of a particle the higher the
probability of drawing it many times.
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Algorithm 3 Particle filter
1. initialize the particles, {xi0}Ni=1 ∼ p(x0) for t = 1
2. Predict the particle by generating Ni.i.d samples according to
x˜it ∼ p(xt|xit−1) for i = 1, . . . , N (4.55)
3. Compute the importance weights {x˜it}Ni=1
w˜it = p(yt|x˜it) for i = 1, . . . , N (4.56)
normalize to wit =
w˜it∑N
j=1 w˜
j
t
(4.57)
4. Resample: For each particle x˜it draw a new particle x
i
t according to
P (xit = x˜
i
t) = w
j
t for j = 1, . . . , N (4.58)
5. t := t+ 1 and go to step 2
In next section, the performance of the previously introduced filter will be compared when
used to estimate the states of the inflammatory model given by Equation (2.1-2.1).
Remark 4.2. The metrics used to evaluate the estimator performance are the root mean
squared error (RMSE) and the normalized estimation error squared (NEES) [6]. The
consistency being satisfied if the actual mean square error (MSE) matches the filter-
calculated covariance, i.e, the following equality is satisfied. i.e.,
E
[
[xt − xˆt|t][xt − xˆt|t]T
]
= Pt|t (4.59)
4.5 Simulation Results
Three state estimation algorithms are simulated with respect to our model. Note that the
average RMSE provides us with a concise metric of the accuracy of a given estimator, while
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Table 4.1: Variability of the model parameters
Parameter Parameter Ranges
P0 0.0 – 1.0
CA0 0.0938 – 0.1563
kpg 0.3 – 0.6
kcn 0.03 – 0.05
knd 0.015 – 0.025
knp 0.075 – 0.125
kcnd 36.0 – 60.0
knn 0.0075 – 0.0125
the NEES is used for evaluate the estimator consistency. The consistency being satisfied if
the actual mean square error (MSE) matches the filter-calculated covariance. The closer to 1,
the more credible is the estimator. The test is performed over 1000 Monte Carlo simulations
for the particle filter and the measurements corresponding to N and Ca are generated from a
reference patient model (See [24] ). These values are used in all cases.. The compared filters
are (i) EKF, a widely used approach in nonlinear system, (ii) Unscented Kalman Filter and
(iii) The standard Particle Filter (PF). For the results presented in this section, the inputs up
(See Eq 2.2) and ua (See Eq 2.4) were generated by the nonlinear model predictive control
presented in [24] and are used for different nonlinear state estimation algorithms. In our
implementation, the continuous system model (Eq 2.1-Eq 2.4) is discretized with time step
h = 1 hour. The initial conditions are specific for each patient, which means that each
modeled patient will start from different initial condition. Notice that we are working with
virtual patients modeled by choosing some parameters within a range a range given in Table
6.1.
For the results shown in Figure 4.1, the measurements were corrupted by zero mean
white gaussian noise, with standard deviation σe = 0.01, and the process noise is chosen
to be σv = 0.001. Figure 4.1 represents a simulation of the first patient model. It shows a
comparison of different state estimation algorithms. It is important to notice that a value
of Q = 0.01 will cause both EKF and UKF for most patient simulation to diverge, i.e., the
covariance matrix for both filters becomes ill-conditioned. Figure 4.2 shows the root mean
square error corresponding to Fig 4.1. Notice that the EKF fails to give a good estimate.
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Figure 4.1: State estimation (EKF, UKF, PF) for patient 1
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Figure 4.2: Squared Error (SE) of estimated states for Patient 1
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Table 4.2: RMSE and NEES for Patient 1
Virtual Patient 1
RMSE
NEES
P N D Ca
EKF 0.0128 0.3614 13.8958 0.1013 5e+8
UKF 0.0200 0.0589 0.7449 0.0528 12.74
PF 0.0071 0.0236 0.0962 0.0347 1.00
Table 4.3: RMSE and NEES for Patient 2
Virtual Patient 2
RMSE
NEES
P N D Ca
EKF 0.2897 0.5121 22.56 0.1179 5e+8
UKF 0.0127 0.0567 0.6525 0.0618 15.07
PF 0.0074 0.0402 0.3271 0.0272 1.01
Table 4.4: RMSE and NEES for Patient 3
Virtual Patient 3
RMSE
NEES
P N D Ca
EKF —— —— —— —— ——
UKF 1.5692 0.0592 0.2239 0.0538 26.87
PF 2.6290 0.0798 0.1565 0.0183 1.0645
Table 4.5: RMSE and NEES for Patient 4
Virtual Patient 4
RMSE
NEES
P N D Ca
EKF —— —— —— ——- ——
UKF 0.0196 0.0575 0.7316 0.0540 16.15
PF 0.0071 0.0209 0.0624 0.0323 1.008
Figure 4.3 is another simulation corresponding to patient 3. The behavior of the estimates
are different from the first Figure. This is basically due to the high level of pathogen (1.0017)
at the initial condition. UKF and PF were still able to track the states. Table 4.2 to 4.5
show a summary of the state estimation simulation corresponding to 4 patients. It is clear
that the EKF estimates are inaccurate, specifically for patient 3 and 4, where they diverge.
As expected, the PF and UKF attain better estimation accuracy (RMSE) than the EKF.
The NEES values for PF are significantly better than the remaining filters. Interestingly, the
UKF performs quite accurately, sometimes as accurately as PF, though this is not always
guaranteed when high values of measurement and process noise are present. The increase
of number of particles for the PF did not give a considerable improvement for this kind of
problem. However for higher values of noise the PF showed more stability and resulted in a
better estimation.
4.5.1 Further simulation results with the particle filter
In this section, we want to continue with the particle filter and emphasize furthermore its
performance with respect to the number of chosen particles. We simulate a single realization
with T = 168 observations using the parameters in [24] . The process and measurements
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Figure 4.3: State estimation (EKF, UKF, PF) for patient 3
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Table 4.6: The logarithms of the absolute value of the error (bias) and the mean square
error for various values of particles
N 5 10 20 50 150 250 500
log-bias -4.61 -4.67 -4.69 -4.72 -4.73 -4.73 -4.73
log-MSE -8.85 -8.96 -8.99 -9.02 -9.03 -9.03 -9.04
noise are given by σv = 0.0001 and σe = 0.001 respectively. The initial state is x0 = (P =
0.2, N = 0.02, D = 0.5, Ca = 0.01).
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Figure 4.5: The logarithms of the absolute value of the error (bias) and the mean square
error for various values of particles
We choose to put side by side two measures of accuracy for the particle filter, the bias
and the mean square error of the state estimate while increasing gradually the number of
particles from 5 to 500. These are computed as follows
Bias(xˆNt|t) =
1
T
T∑
t=1
∣∣xˆNt|t − x∣∣, MSE(xˆNt|t) = 1T (xˆNt|t − x)2 (4.60)
where x is the true state. We can see from Table 4.6 and Figure 4.6 that a number of particle
over N = 100 would not reduce either the Bias or the MSE.
38
0 50 100 150
0.
0
0.
2
0.
4
0.
6
0.
8
Time (Hour)
 S
ta
te
s
P
N
D
Ca
Figure 4.6: A simulated set of 100 realization (dotted line) for the pathogen (P ), Pro-
inflammatory mediator (N), the Damage (D) and the anti-inflammatory mediator (Ca)
together with their corresponding true state (slide line) using particle filter with N = 20,
σv = 0.0001, σe = 0.001
4.6 Concluding remarks
A comparative study was realized with making sure that each state estimator processes
the same data in order to ensure a fair comparison of the 4 patient model. These models
were generated from choosing the parameters in (Eq2.1-Eq2.4) within a known range. The
simulation results show that good estimation were obtained for the UKF although it is
important to mention that this filter failed to converge when high process noise with
measurement noise was chosen. The EKF was the more sensitive to noise and failed in
some simulation to converge. The PF indeed showed better estimate for most simulations
and better stability with respect to different noise. Although PF requires more time to
run all Monte Carlo simulations, it remains the more interesting choice, especially since the
sampling time is considered to be 1 hour and it deals better with non Gaussian noise.
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Chapter 5
Nonlinear Parameter Estimation
In this chapter we are interested in solving the parameter inference problem for a nonlinear
state space models (SSM) that is defined by the ODE’s of our inflammatory immune model.
This is an important problem since often, the parameters that defines the inflammatory
immune model vary from one patient to another and in practice it would be interesting to
provide a good estimate of these parameters given the available set of measurements. The
major problem with Bayesian inference in SSM is that it is an intractable problem, that is
mainly the reason why the use of Monte Carlo simulations becomes helpful to create some
empirical approximation of the target distribution. As we saw with the state estimation
framework, the objective here is to estimate the parameter θ given the set of measurements
y1:T . The target distribution is given by
πθ(θ) = p(θ|y1:T ) = p(θ)p(y1:T |θ)∫
p(θ(k))p(y1:T |θ(k))dθ(k) (5.1)
where p(θ) and p(y1:T |θ) represent the parameter prior distribution and the likelihood of the
measurements, respectively. The denominator can be seen as a scaling factor, it is usually
referred to as the marginal likelihood. Markov chain Monte Carlo methods (MCMC) [83] are
mainly presented by two main tools (Metropolis-Hastings and Gibbs sampler) in which the
objective is to create a Markov chain to sample from πθ(θ). Particle MCMC algorithms can be
thought of as a natural approximation to standard and ‘idealized’ MCMC algorithms which
can not be implemented in practice [1]. The idea behind MCMC is to simulate a Markov
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chain {θ(m)}m≥1. The chain is constructed in such a way that its stationary distribution
coincides with the so called target distribution of interest, i.e., p(θ|y1:T ). In this chapter
we focus our attention on an MCMC algorithm known as the particle Metropolis-Hastings
(PMH; [1]) algorithm.
It is interesting to note that in order to solve a parameter inference problem we are
required to solve a state inference problem. The problem appears when computing the
likelihood.
pθ(y1:T ) = pθ(y1)
T∏
t=2
pθ(yt|y1:T ) (5.2)
The predictive likelihood will be given according to
pθ(yt|y1:t−1) =
∫
gθ(yt|xt)fθ(xt|xt−1)pθ(xt−1|y1:t−1)dxtdxt−1 (5.3)
where pθ(xt−1|y1:t−1) denote the unknown filtering distribution. As seen in previous chapter,
a recursion update of the later distribution is made possible thanks to the particle filter.
Equivalently (5.3) can be expressed as follows
pθ(yt|y1:t−1) =
∫
gθ(yt|xt)pθ(xt|y1:t−1)dxt (5.4)
5.1 Overview of the PMH sampler
The main goal in PMH is to approximate the intractable target distribution πθ(θ) using
empirical approximation based on Monte Carlo methods. It is important to simulate samples
from the posterior distribution when the later has reached stationarity. Usually the initial
transient phase is referred to as the burn-in phase and is discarded.
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5.1.1 Markov chain
The Markov chain is constructed essentially in two steps. The first step is to propose a
candidate parameter θ(k) from a proposal distribution q(θ(k)|θ(k−1)) given the previous state
of the Markov chain denoted by θ(k−1). A good choice of the proposal is important and
the user is supposed to choose a distribution that at least cover the support of the target
distribution πθ(θ). The second step consists of whether to change the state to θ
(k) or remain
in the current state θ(k−1). This decision is based on what is called the acceptance probability,
computed as
β(θ(k), θ(k−1)) = min
{
1,
πθ(θ
(k))
πθ(θ(k−1))
q(θ(k−1)|θ(k))
q(θ(k)|θ(k−1))
}
(5.5)
The acceptance probability β gives the probability of assigning the candidate parameter
as the next state of the Markov chain. The intuition for β is that we accept values θ(k) that
increases the value of the target when compared with the previous state θ(k−1). Note that a
small decrease in the posterior value is allowed for the purpose of facilitating the exploration
of the entire posterior.
Remark 5.1. The acceptance ratio above can be expressed as follows
πθ(θ
(k))
πθ(θ(k−1))
q(θ(k−1)|θ(k))
q(θ(k)|θ(k−1)) =
p(θ(k)|y1:T )
p(θ(k−1)|y1:T )
q(θ(k−1)|θ(k))
q(θ(k)|θ(k−1)) (5.6)
=
p(y1:T |θ(k))p(θ(k))
p(y1:T |θ(k−1))p(θ(k−1))
q(θ(k−1)|θ(k))
q(θ(k)|θ(k−1)) (5.7)
where we made use of the Bayes formula. The scaling factors cancel out.
To implement the PMH algorithm we are required to select a parameter proposal distribution.
A Gaussian random walk will be used and is given by
q(θ(k)|θ(k−1)) = N (θ(k); θ(k−1), 2) (5.8)
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where  is the standard deviation of the increment. The acceptance probability (5.5) can be
simplified since the Gaussian proposal is a symmetric distribution.
β(θ(k), θ(k−1)) = min
{
1,
p(y1:T |θ(k))p(θ(k))
p(y1:T |θ(k−1))p(θ(k−1))
}
(5.9)
where the distribution p(θ) represent the parameter’s prior distribution. For implementation
purposes the prior will mostly be chosen as an inverse Gamma distribution.
5.1.2 Approximating the acceptance probability
To finally be able to implement the acceptance probability (5.9) the likelihood p(y1:T |θ)
needs to be estimated. From (5.2) and (5.3) it is clear that we need to use the particle
filter. Similarly to the Kalman filter, the PF computes a good estimate of the filtering
distribution, and also provides an approximation of the likelihood pθ(y1:T ), which is important
for parameter identification problems. This approximation is given (See also [74]) as follows
pˆNθ (y1:T ) =
T∏
t=1
{ 1
N
N∑
i=1
w¯it
}
(5.10)
where {w¯it}Ni=1 represent the unnormalized importance weights. The expression (5.10) is
derived using the factorization (5.4) and by noting the one-step predictive likelihood (4.38)
can be approximated by
pˆ(yt|y1:t−1) =
∫
gθ(yt|xt)pˆθ(xt|y1:t−1)dt (5.11)
and since
pˆθ(xt|y1:t−1) =
∫
fθ(xt|xt−1)
N∑
i=1
wit−1δxit−1(xt−1) (5.12)
=
N∑
i=1
wit−1fθ(xt|xt−1) (5.13)
43
where we used the fact that the empirical approximation of the filtering distribution at
time t− 1 is given by according to
pˆθ(xt−1|y1:t−1) =
N∑
i=1
wit−1δxit−1(xt−1) (5.14)
Finally, the approximated likelihood is derived as follows
pˆ(yt|y1:t−1) =
∫
gθ(yt|xt)pˆθ(xt|y1:t−1)dt (5.15)
=
1
N
N∑
i=1
gθ(yt|xit) =
1
N
N∑
i=1
w¯it, (5.16)
where {xit}Ni=1 are samples simulated from the approximate distribution pˆθ(xt|y1:t−1)
We use the logarithm so that (5.10) simplifies to
pˆNθ (y1:T ) =
T∑
t=1
{[
log
N∑
i=1
w¯
(i)
t
]
− logN
}
(5.17)
5.1.3 PMH algorithm
The following algorithm summarizes different steps of the particle Metropolis-Hastings
algorithms.
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Algorithm 4 Algorithm for PMH
1: Step 1: Initialize, k = 0,
2: (a) set θ(0) arbitrarily and
3: (b) run an SMC algorithm targeting pθ(0)(x1:T |y1:T ), sample X1:T (0) ∼ pˆθ(0)(·|y1:T ) and
let pˆNθ(0)(y1:T ) denote the marginal likelihood estimate.
4: Step 2: for, iteration k ≥ 1,
5: (a) sample θ(k) ∼ q(·|θ(k−1)),
6: (b) run an SMC algorithm targeting pθ(k)(x1:T |y1:T ), sample X ′1:T (0) ∼ pˆθ(k)(·|y1:T ) and
let pˆN
θ(k)
(y1:T ) denote the marginal likelihood estimate, and
7: (c) with probability
β(θ(k), θ(i−1)) = min
{
1,
pˆN(y1:T |θ(k))p(θ(k))
pˆN(y1:T |θ(k−1))p(θ(k−1))
}
(5.18)
8: set θ(k) = θ(k), X1:T (i) = X
′
1:T and pˆθ(k)(y1:T ) = pˆ
N
θ(k)
(y1:T ); otherwise,
9: set θ(i) = θ(k−1), X1:T (i) = X1:T (k − 1) and pˆθ(i)(y1:T ) = pˆNθ(k−1)(y1:T ).
Remark 5.2. The decision of accepting or rejecting the proposed parameter is practically
implemented by simulating a uniform random variable w over [0, 1], then we accept θ(k) if
w < β(θ(k), θ(i−1)) by storing it together with its corresponding log-likelihood as the current
state of the Markov chain.
In next section, some reference parameters that vary from one virtual patient to another
will be estimated using the algorithm introduced in previous section.
5.2 Numerical simulations for parameter inference
In this section, we make use of the PMH algorithm to estimate the posterior of a set of
parameters given in table 5.1. These parameters vary from one patient to another. The
remaining parameters that define the inflammatory immune model are considered to be
fixed, and there is no need to estimate them.
Let’s consider the inflammatory immune model given in the chapter 1
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Remark 5.3. the model is given in continuous time, it is therefore discretized with respect
to an Euler scheme with sampling period T = 1. The parameters to be estimated are given
in Table 1.
Table 5.1: True parameters together with their variability range
Parameter Parameter Ranges
kpg = 0.52 0.3 – 0.6
kcn = 0.04 0.03 – 0.05
knd = 0.02 0.015 – 0.025
knp = 0.1 0.075 – 0.125
kcnd = 48 36.0 – 60.0
knn = 0.01 0.0075 – 0.0125
Before starting the simulation, we generate a set of measurements data Y1:168 with a
noise variance corresponding to R = 0.1 and a process noise Q = 0.00001. We use a
proposal step length  = 0.05 and initialize the Markov chain for the first parameter to
estimate, i.e., kpg=1. For all simulations, the initial state is selected to be [P,N,D,Ca] =
[0.2, 0.02, 0.5, 0.01]. The small state values are chosen simply to keep the system in the stable
region since we are not using any type of control input. The number of particle chosen is
N = 20. The parameter prior p(θ) in (5.9) is selected to be an inverse Gamma distribution
with a = 2, and b = 2 for the shape and scale values respectively for estimating kpg. The
algorithm is run for K = 500 iterations and we discard the first 100 iterations as burn-in.
This means that we use only the last 400 samples to construct the empirical approximation
of the parameter posterior distribution.
Remark 5.4. The number of iterations does not have to be fix and can be increased if we
see the markov chain needs more iterations to converge.
In all the simulations that will follow, for each parameter the resulting posterior parameter
will be presented as histogram together with the kernel density estimate. The state of the
Markov chain at each iteration will also be plotted. The bottom part of each figure will
highlight the the resulting estimate of the auto-correlation function (ACF). The dotted lines
in the figures represent the posterior mean. A discussion of the estimated parameters will
be given after the simulation results are presented.
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Figure 5.1: The estimate of the target distribution using PMH algorithm. Upper: The
estimate of πkpg(kpg) presented as a histogram and kernel density estimate (solid line).
Middle: The state of the Markov chain for 500 iterations. Lower: the estimated ACF for
the Markov chain. Dotted lines in the upper and middle plot indicate the estimate of the
posterior mean (kpgmean = 0.549). The dotted lines in the lower plot indicate the 95%
confidence intervals of the ACF coefficients
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In Figure 5.2, the resulting posterior estimate and the chain are clearly concentrated
around the posterior mean estimate given by kpg = 0.549.
For estimating kcn we initialize it with kcn = 0.1. The parameter that defines the inverse
Gamma prior, i.e., the shape and scale are changed to a = 0.1 and b = 0.1. The step size
for the proposal distribution is  = 0.01, all the remaining initialization remains the same.
In Figure 5.3 the posterior mean is found to be kcnmean = 0.0368.
In Figure 5.4, we see that Markov chain converges to the posterior mean given by kndmean =
0.0292. The parameter knd is initialized with knd = 0.1, the step size for the proposal is
 = 0.01 and the parameter of the inverse Gamma are a = 0.1 and b = 0.1. The remaining
initialization variables remains the same.
For knp estimation we initialize it with knp = 0.075 which is the minimum value in the
parameter range as seen in the table 5.1. We make use of the following step size for the
proposal  = 0.02, the inverse Gamma parameters are a = 0.1, b = 0.1. In Figure 5.6 the
posterior mean value is knp = 0.118
An initial value for knn = 0.1 is used. The step size for the proposal is selected to be
 = 0.01. The inverse Gamma parameters are given by a = 0.05 and b = 0.05.
5.2.1 Discussion
We note from previous section that the chain and the posterior estimate’s mean for most
parameters was close to the true parameter. The auto-correlation function tells us about
the quality of the Markov chain, i.e., it is a measure of how independent different samples
are from our posterior (target) distribution. So essentially, lower auto-correlation indicates
more independent samples. Highly correlated samples simply won’t represent accurately the
posterior distribution and consequently will be reflected in the accuracy of the estimated
parameter. It has been observed that the choice of the proposal  influences the correlation
of the Markov chain and therefore the variance in the estimate. If the proposal step length
is small it will result in a smaller variance for the posterior, however the samples will be
more correlated, resulting in an ACF value larger than zero. Increasing the step length
will provide more varied samples that are less correlated and this will result in a better
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Figure 5.2: The estimate of the target distribution using PMH algorithm. Upper: The
estimate of πkpg(kpg) presented as a histogram and kernel density estimate (solid line).
Middle: The state of the Markov chain for 500 iterations. Lower: the estimated ACF for
the Markov chain. Dotted lines in the upper and middle plot indicate the estimate of the
posterior mean (kpgmean = 0.549). The dotted lines in the lower plot indicate the 95%
confidence intervals of the ACF coefficients
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Figure 5.3: The estimate of the target distribution using PMH algorithm. Upper: The
estimate of πkcn(kcn) presented as a histogram and kernel density estimate (solid line).
Middle: The state of the Markov chain for 500 iterations. Lower: the estimated ACF for
the Markov chain. Dotted lines in the upper and middle plot indicate the estimate of the
posterior mean (kcnmean = 0.0368). The dotted lines in the lower plot indicate the 95%
confidence intervals of the ACF coefficients
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Figure 5.4: The estimate of the target distribution using PMH algorithm. Upper: The
estimate of πknd(knd) presented as a histogram and kernel density estimate (solid line).
Middle: The state of the Markov chain for 500 iterations. Lower: the estimated ACF for
the Markov chain. Dotted lines in the upper and middle plot indicate the estimate of the
posterior mean (kndmean = 0.0292). The dotted lines in the lower plot indicate the 95%
confidence intervals of the ACF coefficients
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Figure 5.5: The estimate of the target distribution using PMH algorithm. Upper: The
estimate of πKnp(knp) presented as a histogram and kernel density estimate (solid line).
Middle: The state of the Markov chain for 500 iterations. Lower: the estimated ACF for
the Markov chain. Dotted lines in the upper and middle plot indicate the estimate of the
posterior mean (knpmean = 0.118). The dotted lines in the lower plot indicate the 95%
confidence intervals of the ACF coefficients
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Figure 5.6: The estimate of the target distribution using PMH algorithm. Upper: The
estimate of πKnn(knn) presented as a histogram and kernel density estimate (solid line).
Middle: The state of the Markov chain for 500 iterations. Lower: the estimated ACF for
the Markov chain. Dotted lines in the upper and middle plot indicate the estimate of the
posterior mean (knnmean = 0.034). The dotted lines in the lower plot indicate the 95%
confidence intervals of the ACF coefficients
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estimate of the posterior. The tuning of the proposal step length is therefore important to
obtain an efficient exploration of the parameter posterior. One other important user-defined
parameter is the choice of the parameter prior p(θ), which we have chosen as an inverse
Gamma distribution. This choice was not random, since the distribution covers the support
of the target distribution and does not generate negative values.
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Chapter 6
Nonlinear control
An efficient control of an acute inflammatory response to a severe infection is crucial to
restore the patient to a healthy state. Given the previously introduced model, we use the
concentration of the pro and anti-inflammatory mediator, i.e., up and ua to decrease the
level of pathogen (P ) and damage (D) while trying to minimize the total dose administered.
We consider two different routes: a model based approach, and a model free approach. The
first relies on optimal control, where the problem is solved considering an L2 objective, and
the case when the objective is linear in the control. The second does not take into account
the system dynamic equations and will be presented in chapter 7. Before introducing the
result on optimal control we see in next section the limitation of the backstepping conrol
approach when applied to the inflammatory immune model.
6.1 Backstepping control
Backstepping is a recursive design methodology developed in the 90’s by Kokotvic [56] where
the construction of feedback control laws and associated Lyapunov function is systematic
if we consider a special class of nonlinear dynamical system i.e., strict-feedback form.
Backstepping is used to force a nonlinear system to behave like a linear system in a
new set of coordinates [60]. Feedback linearization requires cancellation of nonlinearities,
sometimes important for stabilization and tracking. Backstepping however, offers more
flexibility to avoid cancelling usefull nonlinearities and focus more on the main objective
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of stabilization and tracking rather than that of linearization. In next subsection the
backstepping methodology will be used to derive the controls that will stabilize our virtual
patient to its healthy equilibrium. The difficulties encountered will be discussed.
6.1.1 Backstepping control for the immune model
Consider the following immune response model:
dx1
dt
= ax1 − bx21 −
cx1
d+ ex1
− f
g + x24
x1x2 (6.1)
= fx1 (6.2)
dx2
dt
=
hx1 + ix2 + jx3
kx1 + lx2 +mx3 + nx24 + o
− px2 + up(t) (6.3)
= fx2 + up (6.4)
dx3
dt
=
qx62
(r + sx24)
6 + tx62
− μdx3 (6.5)
= fx3 (6.6)
dx4
dt
= sc +
ux2 + vx3
g + x24 + gx2 + wx3
− μcx4 + ua (6.7)
= fx4 + ua (6.8)
We are interested to design a backstepping conrol to be able to satisfy both objectives:
P → 0 and D → 0, respectively x1 → 0 and x3 → 0, while maintainting the stability of the
system.
Let z1 = x1. Choose the following virtual conrol ζ1 =
fx2
g+x24
, and design a stabilizing
function. α1(x1) = γ − bx1. Such that γ = a+C1. Where C1 is a design variable expressing
the rate of the convergence.
Let z1 = x1 − xref . The reference is zero in our case. To design a stabilizing function α1 for
ζ1 with respect to V1(x1) =
1
2
x21, we examined the inequality V˙1 < 0, that is
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V˙1 = x1
(
ax1 − bx21 −
cx1
d+ ex1
− x1ζ1
)
(6.9)
z2 = ζ1 − α1(x1) (6.10)
V˙1 = − cx
2
1
d+ ex1
− C1x21 − z2x21 (6.11)
Assume that z2 will converge to zero. This will be the next objective. Consider the followign
Lyapunov function
V2 =
1
2
z22 (6.12)
Now, design a controller such that to make V˙2 = z2z˙2 < 0
z2 =
fx2
g + x24
− γ + bx1 (6.13)
V˙2 = z2
(
f
g + x24
fx2 −
2fx4x2
(g + x24)
2
fx4 + bfx1 +
f
g + x24
up − 2fx4x2
(g + x24)
2
ua
)
(6.14)
Choose the control combination to make the system stable
f
g + x24
up − 2fx4x2
(g + x24)
2
ua = − f
g + x24
fx2 +
2fx4x2
(g + x24)
2
fx4 − bfx1 (6.15)
up − 2x4x2
(g + x24)
ua = −fx2 +
2x4x2
(g + x24)
fx4 −
b
f
(g + x24) + x
2
1 (6.16)
Now, it remains to design the combination of control to satisfy the second control
objective,i.e., z3 = x3 − xref2. The reference in this case, also will be zero. Consider the
Lyapunov function given by V3 =
1
2
x23. Choose the virtual control to be ζ2 =
qx62
(r+sx24)
6+tx62
and
α2 = −C3x3. We want to make sure the the error z4 = qx
6
2
(r+sx24)
6+tx62
+ C3x3 vanishes to zero
V˙3 = x3 (z4 + α2 − μdx3) (6.17)
= x3z4 − (C3 + μd)x23 (6.18)
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Assume that now that z4 will converges to zero. The extra term in the above Lyapunov
equation will be cancelled in the next step. Choose V4 =
1
2
z24
V˙4 = z4
{
6qx52 (sx
2
4 + r)
6(
(sx42 + r)
6 + tx26
)2fx2 + 6qx52 (sx24 + r)6(
(sx42 + r)
6 + tx26
)2up(t)− 12 sqx26 (sx42 + r)5 x4(
(sx42 + r)
6 + tx26
)2fx4
− 12 sqx2
6 (sx4
2 + r)
5
x4(
(sx42 + r)
6 + tx26
)2ua + C3fx3
}
(6.19)
After simplification and choosing the control combination to ensure V˙4 < 0 we obtain the
following
up − 2sx2x4
sx24 + r
ua = −fx2 +
2sx2x4
sx24 + r
fx4 +
((sx24 + r)
6 + tx62)
2
6qx52(sx
2
4 + r)
6
(−x3 − C4z4 + C3fx3) (6.20)
6.1.2 Dynamic extension for input output decoupling
There are actually two approaches to solve the singular decoupling problem. One involve
incorporating an integrator to one channel and differentiating the outputs to obtain a new
decoupling matrix, this is called dynamic extension. The other approache requires using
backstepping idea by closing the loop at each design steps. the resulting contol law based
on backstepping design is static state feedback; the decoupling control based on dynamic
extension is a dynamic state feedback. Although the idea of decoupling by dynamic extension
is simpler, it involves however differentiating very complicated expression reslting in terms
that are not easy to follow. This is the reason we will focus on the approach that uses
backstepping in the design.
First our control objective is to control both pathogen and damage and drive each state
to zero. If we let z1 = x1
z˙1 = ax1 − bx21 −
cx1
d+ ex1
− f
g + x24
x1x2 (6.21)
Choose the following virtual conrol ζ1 =
fx2
g+x24
, and design a stabilizing function. α1(x1) =
γ − bx1. Such that γ = a + C1. Where C1 is a design variable expressing the rate of the
58
convergence. The error term z2 will be given as
z2 =
fx2
g + x24
− γ + bx1 (6.22)
Note: We don’t really have to include bx1
Now differentiating previous error, we obtain the following
z˙2 =
f
g + x24
fx2 −
2fx2x4
(g + x24)
2
fx4 + bfx1 +
f
g + x24
up − 2fx2x4
(g + x24)
2
ua (6.23)
We do the same thing with the second control objective, i.e., choose
z3 = x3 (6.24)
z˙3 =
qx62
(r + sx24)
6 + tx62
− μdx3 (6.25)
z4 =
qx62
(r + sx24)
6 + tx62
+ C3x3 (6.26)
Finally after differentiating z4 we obtain the following
z˙2 =
f
g + x24
fx2 −
2fx2x4
(g + x24)
2
fx4 + bfx1 +
f
g + x24
up − 2fx2x4
(g + x24)
2
ua (6.27)
z˙4 = ψ(x)fx2 −
2sx2x4
(sx24 + r)
ψ(x)fx4 + C3fx3 + ψ(x)up −
2sx2x4
sx24 + r
ψ(x)ua (6.28)
ψ(x) =
6qx52(sx
2
4 + r)
6
[(sx24 + r)
6 + tx62]
2
(6.29)
The exact expression for feedback linearization are given according to
z˙2 =
f
g + x24
fx2 −
2fx2x4
(g + x24)
2
fx4 + bfx1 +
f
g + x24
up − 2fx2x4
(g + x24)
2
ua (6.30)
z˙4 = ψ(x)fx2 −
2sx2x4
(sx24 + r)
ψ(x)fx4 + C3fx3 + ψ(x)up −
2sx2x4
sx24 + r
ψ(x)ua (6.31)
ψ(x) =
6qx52(sx
2
4 + r)
6
[(sx24 + r)
6 + tx62]
2
(6.32)
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The previous equations can be written as
⎡
⎣z˙2
z˙4
⎤
⎦ =
⎡
⎣φ2(x)
φ4(x)
⎤
⎦+
⎡
⎣ fg+x24 − 2fx2x4(g+x4)2
ψ(x) −2sx2x4
sx24+r
ψ(x)
⎤
⎦
︸ ︷︷ ︸
E(x)
⎡
⎣up
ua
⎤
⎦
︸ ︷︷ ︸
u
(6.33)
It is easy to verify that determinant of decoupling matrix is zero. Since the constant r = s.g
6.1.3 Dynamic extension with backstepping
We need to redefine the input vector u such that E(x) has only one nonzero vector; we
do this through linear transformation. The matrix P (x) permits such transformation. We
define the new control inputs up1 and ua1 such that
⎡
⎣up
ua
⎤
⎦ =
⎡
⎣1 2x2x4g+x24
0 1
⎤
⎦
︸ ︷︷ ︸
P (x)
⎡
⎣up1
ua1
⎤
⎦ (6.34)
Equation 6.33 becomes
⎡
⎣z˙2
z˙4
⎤
⎦ =
⎡
⎣φ2(x)
φ4(x)
⎤
⎦+
⎡
⎣ fg+x24 0
ψ(x) 0
⎤
⎦
⎡
⎣up1
ua1
⎤
⎦ (6.35)
Choose a state feedback law to stabilize the first channel, z˙2
up1 =
g + x24
f
(
u1 − φ2(x)
)
(6.36)
the second equation in 6.33 becomes
z˙4 = φ4(x) +
(g + x24)
f
ψ(x)
(
u1 − φ2(x)
)
= ν¯1 (6.37)
60
the closed loop system is now given by
z˙2 = u
1 = −K1z2 (6.38)
z˙4 = ν¯
1 = −K2z4 (6.39)
Define ξ2 as the difference between the virtual control ν¯1 and it’s stabilizing function
α¯1 = −K2z4
ξ2 = ν¯1 +K2z4 (6.40)
= φ4(x) +
(g + x24)
f
ψ(x)
(
u1 − φ2(x)
)
+K2z4 (6.41)
The next step will involve differentiating ξ2 and deriving the expression of the second control
ua1 .
ξ2 = φ4(x)− g + x
2
4
f
ψ(x)φ2(x) +
g + x24
f
ψ(x)u1 +K2z4 (6.42)
= ψ(x)fx2 −
2sx2x4
(sx24 + r)
ψ(x)fx4 + C3fx3 −
g + x24
f
ψ(x)
(
f
g + x24
fx2 −
2fx2x4
(g + x24)
2
fx4 + bfx1
)
+
g + x24
f
ψ(x)u1 +K2z4 (6.43)
After some simplification we obtain the following expression for ξ2
ξ2 = C3fx3 −
g + x24
f
ψ(x)bfx1 +
g + x24
f
ψ(x)u1 +K2z4 (6.44)
ξ2 = C3fx3 +
g + x24
f
ψ(x)
[
u1 − bfx1
]
+K2z4 (6.45)
Differentiate ξ2 with respect to time according to
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ξ˙2 = C3
[
ψ(x)fx2 −
2sx2x4
(sx24 + r)
ψ(x)fx4 + ψ(x)up −
2sx2x4
sx24 + r
ψ(x)ua
]
(6.46)
+
g + x24
f
ψ(x)
[
u˙1 − bβ(x)fx1 −
bfx1
g + x24
fx2 +
2bfx1x2x4
(g + x24)
2
fx4 −
bfx1
g + x24
up +
2bfx1x2x4
(g + x24)
2
ua
]
+
g + x24
f
[
u1 − bfx1
] [6q
sf
(
5x42(sx
2
4 + r)
7
((sx24 + r)
6 + tx62)
2
− 12x
10
2 (sx
2
4 + r)
7t
((sx24 + r)
6 + tx62)
3
)
(fx2 + up)
+
6q
sf
(
14sx52(sx
2
4 + r)
6x4
((sx24 + r)
6 + tx62)
2
− 24sx
5
2x4(sx
2
4 + r)
12
((sx24 + r)
6 + tx62)
3
)
(fx4 + ua)
]
−K22z4 (6.47)
β(x) = a− 2bx1 − c
d+ ex1
+
cex1
(d+ ex1)2
− f
g + x24
x2 (6.48)
β′(x) = a− bx1 − c
d+ ex1
+
cex1
(d+ ex1)2
− f
g + x24
x2 (6.49)
Notice that after applying the inverse transformation the original controls are given according
to
up = up1 −
2x2x4
g + x24
ua1 (6.50)
=
g + x24
f
(
u1 − φ2(x)
)− 2x2x4
g + x24
ua1 (6.51)
ua = ua1 (6.52)
Where up1 is given by Equation 6.36.
6q
sf
(
5x42(sx
2
4 + r)
7
((sx24 + r)
6 + tx62)
2
− 12x
10
2 (sx
2
4 + r)
7t
((sx24 + r)
6 + tx62)
3
)
=
ψ(x)(sx24 + r)
sf
[5(sx4 + r)
6 − 7tx62]
x2(sx24 + r)
6 + tx72
= γ1(x)
(6.53)
6q
sf
(
14sx52(sx
2
4 + r)
6x4
((sx24 + r)
6 + tx62)
2
− 24sx
5
2x4(sx
2
4 + r)
12
((sx24 + r)
6 + tx62)
3
)
=
sψ(x)
sf
(7tx4x
6
2 − 5x4(sx24 + r)6)
(sx24 + r)
6 + tx62
= γ2(x)
(6.54)
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After some simplification we obtain the following
ξ˙2 = C3ψ(x)
g + x24
f
(
u1 − bfx1
)− 4x2x4ψ(x)
(g + x24)
ua
+
g + x24
f
ψ(x)
(
u˙1 − bβ′(x)fx1 + bx1u1
)− 4bx1x2x4
(g + x24)
ψ(x)ua (6.55)
+
g + x24
f
[
u1 − bfx1
]
γ1(x)
(
fx2 +
g + x24
f
(
u1 − φ2(x)
))
(6.56)
− 2x2x4
f
(u1 − bfx1)γ1(x)ua + γ2(x)fx4 + γ2(x)ua −K22z4 (6.57)
= φ(x)− ψ(x)
(
4x2x4(1 + bx1)
g + x24
+
2x2x4
f
(u1 − bfx1)γ′1(x)− γ′2(x)fx4
)
ua (6.58)
= φ(x)− φ1(x)ua (6.59)
γ1 = ψ(x)γ
′
1(x) (6.60)
γ2 = ψ(x)γ
′
2(x) (6.61)
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Choose
ua = φ
−1
1
(
φ(x) +K3ξ
2
)
(6.62)
φ(x) = ψ(x)
g + x24
f
[
C3(−K1z2 − bfx1) +K21z2 − bβ′(x)fx1 − bK1z2x1+[
−K1z2 − bfx1
]
γ′1(x)
(
fx2 +
g + x24
f
(−K1z2 − φ2(x))
)]
+ γ2(x)fx4 −K22z4 (6.63)
φ1(x) =
(
4x2x4(1 + bx1)
g + x24
+
2x2x4
f
(u1 − bfx1)γ′1(x)− γ′2(x)fx4
)
ψ(x) (6.64)
z2 =
fx2
g + x24
− γ + bx1 (6.65)
β′(x) = a− bx1 − c
d+ ex1
+
cex1
(d+ ex1)2
− f
g + x24
x2 (6.66)
φ2(x) =
f
g + x24
fx2 −
2fx2x4
(g + x24)
2
fx4 + bfx1 (6.67)
fx1 = ax1 − bx21 −
cx1
d+ ex1
− f
g + x24
x1x2 (6.68)
fx2 =
hx1 + ix2 + jx3
kx1 + lx2 +mx3 + nx24 + o
− px2 (6.69)
fx4 = sc +
ux2 + vx3
g + x24 + gx2 + wx3
− μcx4 (6.70)
ξ2 = C3fx3 +
g + x24
f
ψ(x)
[
−K1z2 − bfx1
]
+K2z4 (6.71)
Notice that it is extremely difficult to check when the derived control ua is not defined;
it is however straightforward to conclude on the case where x2 or x4 or both are zero. We
can conclude from the previous derivations that control approaches relying on algebraic
manipulation are not suitable for the kind of structure provided by the ODE’s of the
inflammatory model, that is mainly the reason that justifies next section
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6.2 Immune Therapeutic Strategies Using Optimal
Controls with L1 and L2 Type Objectives
In this section therapeutic strategies to correct an excessive immune response to pathogenic
infection is investigated as an optimal control problem. The control problem is formulated
around a four dimensional mathematical model introduced in chapter 2 and describing the
inflammatory response to a pathogenic insult with two therapeutic control inputs which
have either a direct pro- or anti-inflammatory effect in the given system. First, we prove
the existence of the optimal control, then Pontryagin’s maximum principle is used to discuss
necessary optimality conditions. We consider both an L1 type objective functional as well
as an L2 type objective. For the former, the presence of singular control will be addressed.
For each case we propose two ways of solving the problem. In the indirect method a two
point boundary value problem (TPBVP) is formulated and then solved numerically with the
forward backward sweep method [63], while in the direct approach, numerical simulations
using a nonlinear programming optimization solver is used to acquire different drug treatment
strategies.
6.2.1 The Optimal Control Problem
The problem we seek to solve is to find a suitable control u = u(t) which minimizes a
certain defined performance index given various constraints. Letting x˙ = f(x(t), u(t)) denote
the model system with time-dependent variables x(t) ∈ R4, controls u(t) ∈ R2; tf the
final time and φ(x(tf )) the value of the objective function, J , at the final time; L the
Lagrangian; C(x(t), u(t)) the mixed state-control inequality constraints; and S(x(t)) the
state-only inequality constraints, the optimal Control Problem (OCP) can be summarized
in the following way:
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(OCP )
⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
minimize
u∈U
J = φ(x(tf )) +
∫ tf
t0
L(x(t), u(t))dt
subject to the following constraints:
x˙ = f(x(t), u(t)) f : R4 × R2 → R4
x(0) = x0 ∈ Rn x0 known initial state
φ(x(tf )) = xf ∈ R4 φ : R4 × R+ → R4
C(x(t), u(t)) ≤ 0 ∈ R2 C : R4+2 → R2
S(x(t)) ≤ 0 ∈ R2 S : R4 → R2
(6.72)
We consider controls that enter linearly into the system. After algebraically rearranging
the expressions in equations (2.1)-(2.4) and renaming the resulting parameter expressions
from a to w as shown in Table 6.1, the model system with controls can now be written as:
x˙ = f(x) + g(x)u =
⎛
⎜⎜⎜⎜⎜⎜⎜⎜⎝
aP − bP 2 − cP
d+eP
− z
g+C2a
PN
hP+iN+jD
kP+lN+mD+nC2a+o
− pN
qN6
(r+sC2a)
6+tN6
− μdD
sc +
uN+vD
g+C2a+gN+wD
− μcCa
⎞
⎟⎟⎟⎟⎟⎟⎟⎟⎠
+
⎛
⎜⎜⎜⎜⎜⎜⎝
0 0
1 0
0 0
0 1
⎞
⎟⎟⎟⎟⎟⎟⎠
⎛
⎝up
ua
⎞
⎠ (6.73)
a = kpg e = kmp i = c
2
∞snrknn m = c
2
∞knd q = c
12
∞kdn
b = kpg
P∞ z = kpnc
2
∞ j = c
2
∞snrknd s = kdn n = knr
c = kpmsm g = c
2
∞ k = c
2
∞knp o = c
2
∞knr t = c
12
∞
d = km h = c
2
∞snrknp l = c
2
∞knn p = kn u = c
2
∞kcn
v = c2∞kcnkcnd r = c
2
∞kdn w = c
2
∞kcnd
Table 6.1: Parameters of the algebraically rearranged immune model with control terms as
given in (6.73).
where f(x) and g(x) represent a vector and a matrix, respectively, that can be easily
inferred from equation (6.73). The state vector is given by x = (P,N,D,Ca)
T and the
control vector by u = (up, ua)
T . The above alternate representation of the system, after
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algebraically rearranging the immune model equations, provides a more useful form for the
differentiation that will be carried out below in solving the control problem and allows a
better understanding of the role of each state in the system. Two case studies will be
investigated: an optimal control problem with L1-type objective (linear cost term) versus
one with an L2-type objective (quadratic cost term) in J .
For the quadratic case the objective functional to be minimized is therefore given as
J(up, ua) =
∫ tf
0
a1P (t)
2 + a2N(t)
2 + a3D(t)
2 + a4Ca(t)
2 + B1up(t)
2 + B2ua(t)
2dt (6.74)
For the linear case, the objective functional is given according to
J(up, ua) =
∫ tf
0
a1P (t) + a2N(t) + a3D(t) + a4Ca(t) +B1up(t) +B2ua(t)dt (6.75)
The goal here, for both functionals is to determine the optimal control pair u∗p and u
∗
a such
that
J(u∗p, u
∗
a) = min
(up,ua)∈U
J(up, ua) (6.76)
where the basic control set is
U = {(up, ua) ∈ (L∞(0, tf ))2| 0 ≤ up(t) ≤ Mp, 0 ≤ ua(t) ≤ Ma, a.e.}
and other state constraints may be considered later.
Note that during our simulation we also added the final cost term to our objective
functional as φ(x(tf )) = P (tf ) + N(tf ) + D(tf ) + Ca(tf ) for the linear case and similarly
φ(x(tf )) = x(tf )
Tx(tf ) = P
2(tf ) + N
2(tf ) + D
2(tf ) + C
2
a(tf ) for the quadratic one. The
optimal state x∗, although satisfying the equality constraints x˙ = f(x(t), u(t)), is further
constrained by the initial and final boundary condition, or point constraints. In our case,
the initial state is x(0) = (P (0), N(0), D(0), Ca(0)) = (0.536, 0.066, 0.0477, 0.1635) for
patient 1 and (1.0017, 0.0711, 0.0732, 0.1314) for patient 2 and the final state for each is
x(tf ) = (P (tf ), N(tf ), D(tf ), Ca(tf )) = (0, 0, 0, 0.125).
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The approach known as the indirect method, used in our previous publications [9, 8],
attempts to preserve the infinite dimensional nature of the problem [98] and uses Pontraygin’s
maximum principle to solve a TPBVP. The disadvantage of the indirect method lies in the
fact that the boundary problem with the transversality condition is often difficult to solve,
and can become further encumbered in the presence of path constraints. In this work, we take
an approach that finds a finite dimensional representation necessary to solve the problem.
Such approaches are known as direct methods and to achieve this, we discretize the state
and/or control variables and formulate a nonlinear programming problem (NLP) to solve
the optimization problem.
6.2.2 Existence of an optimal control
Practically, before attempting to numerically find an optimal control solution, it is interesting
to see if an optimal control indeed exists. The existence of an optimal control for the L1 and
L2 objective functional can be obtained from standard results like in [35, 34] or by using a
weak convergence direct approach [53]. These results use the bounded range of the controls
and the states as well as the structure of the ODE system being linear in the controls. Also
the right hand sides of the ODEs are continuous functions of the states. An existence proof
will be presented for the case of bounded control.
Assumption 1. If the generated inflammatory doses up and ua and the initial states are non-
negative (i.e. up(t) ≥ 0, ua(t) ≥ 0 ∀t and P (0) ≥ 0, N(0) ≥ 0, D(0) ≥ 0, Ca(0) ≥ 0)
then the solution trajectories of the differential equations (2.1)-(2.4) remain in the positive
octant.
This is a reasonable assumption since the states represent biological entities that are
inherently positive. Following results by [35] we proof the existence of the optimal control
for bounded controls. Note that the same proof can be used for the L1 objective case. The
only difference would be in point 5 of theorem 6.1.
Theorem 6.1. Using assumption 1 , and given the quadratic objective in Equation (6.74),
where U = {(up(t), ua(t)), are piecewise continuous, 0 ≤ up ≤ Nmax, 0 ≤ ua ≤ Camax } there
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exist an optimal control pair u∗p and u
∗
a that minimizes the objective functional, i.e Eq. 6.76
is verified.
Proof. To prove the theorem the following conditions have to be verified
1. The class of all initial conditions [x0 , u] such that u is a Lebesgue integrable function
on [t0 , t1] with values in an admissible control set, together with the corresponding
states is not empty
2. The admissible control set is closed and convex
3. The right hand side of the system is continuous and bounded by a linear function in
the state and control
4. The integrand of the objective function is convex in both controls.
5. There exist constants c1, c2, and β > 1 such that the integrand of the objective
functional satisfies
L(P,D, up, ua) ≥ c1(|up|2 + |ua|2)β/2 − c2 (6.77)
We use results in Thm 9.2.1 by [68] to verify the first point. This basically shows the
existence of solutions of our immune system ODE (2.1)-(2.4) knowing that we have bounded
coefficients and the solutions are bounded on the finite time interval. This holds if assumption
1 is verified. The set U is closed and convex by definition. For the third condition, the right
hand side of the dynamic equations can be ensured to be continuous again if assumption 1
can be satisfied, to avoid any discontinuity in the fraction found in Equation (2.1), (2.2 )
and (2.4 ). The linear bound can be derived according to
|f(x(t),u(t))| ≤
∣∣∣∣∣∣∣∣∣∣∣∣
⎛
⎜⎜⎜⎜⎜⎜⎝
a 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
⎞
⎟⎟⎟⎟⎟⎟⎠
⎛
⎜⎜⎜⎜⎜⎜⎝
x1
x2
x3
x4
⎞
⎟⎟⎟⎟⎟⎟⎠
∣∣∣∣∣∣∣∣∣∣∣∣
+
∣∣∣∣∣∣∣∣∣∣∣∣
⎛
⎜⎜⎜⎜⎜⎜⎝
0
α1 + up
α2
α3 + ua
⎞
⎟⎟⎟⎟⎟⎟⎠
∣∣∣∣∣∣∣∣∣∣∣∣
≤ C1(|x|+ |u|) (6.78)
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Where f(x(t),u(t)) is the vector function defined in Equation (3.16)
∣∣∣∣ hx1 + ix2 + jx3kx1 + lx2 +mx3 + nx24 + o
∣∣∣∣ ≤
√
h2 + i2 + j2√
k2 + l2 +m2
= α1 (6.79)∣∣∣∣ qx62(r + sx24)6 + tx62
∣∣∣∣ ≤ qt = α2 (6.80)∣∣∣∣sc + ux2 + vx3g + x24 + gx2 + wx3 − μcx4
∣∣∣∣ ≤ sc+
√
u2 + v2√
g2 + w2
= α3 (6.81)
The integrand L(P,D, up, ua) = A1P (t)2 + A2D(t)2 + B1up(t)2 + B2ua(t)2 is obviously convex
in both controls. For β = 2 and c2 = 0 One can see the last condition holds.
6.2.3 Numerical solution of optimal control problem
Numerical solutions of our optimal control problem are found by applying direct optimization
via the use of PSOPT [13], an open source pseudospectral optimization software package.
PSOPT is written in C++ and uses direct collocation methods, including Legendre
or Chebyshev pseudospectral discretization as well as local transcriptions such as the
trapezoidal or Hermite-Simpson integration methods. Sparse nonlinear programming is then
used to find local optimal solutions. PSOPT can be interfaced to, IPOPT, the open source
Interior Point Optimization solver ([104]) for solving large scale optimization problems. This
solver will be used for all simulations in this work.
A good example that highlights the relationship between nonlinear programming (NLP)
and optimal control can be found in [18], where the Karush-Kuhn-Tucker (KKT) necessary
conditions approach the necessary condition of the maximum principle as the number of
nodes increases (i.e. as the step size h → 0. The NLP Lagrange multipliers can be interpreted
as a discrete approximation of the adjoint variables found using the maximum principle,
which motivates the following remark.
Remark 6.2. Using the Lagrange multipliers provided by PSOPT, the numerical solutions
can be verified by showing that they satisfy the necessary conditions of optimality with good
accuracy.
70
We observed that the Hermite-Simpson integration method provided better convergence
results and accuracy (O(h4)) ([13]), when compared to either trapezoidal methods provided
in PSOPT which are known to have an accuracy of O(h2). The pseudospectral discretization
method of Legendre or Chebyshev proved to be slow to converge and not accurate although
these have been successfully applied elsewhere (e.g., [14], [86]). In addition, since we found
that the solution of the optimal control problem of the previously mentioned two patients
to be very similar, we will focus on providing simulation results related to the patient with
a septic outcome.
Remember that the control objectives in this work are to minimize the levels of pathogen
and of damage such that P = 0 and D = 0, respectively, while at the same time making sure
to use the lowest possible dosing amounts. In addition, we have the following assumption
A number of grid points N = 1000 is used together with a tolerance of 10−6 for the NLP
solver specifications. All simulations are performed for a week (168hours) and, therefore, the
sampling period, given the number of grid points, is every 0.168 hours. For each simulation
we report the cost function Jz, where z specifies the corresponding subsection in which the
particular cost function is defined; the entry and exit times, t1 and t2, respectively, of the
singular arc, if one exists in the case where an L1 type objective function is used; and the
numerical value of the states, P , N , D, and Ca at the final time, tf . Note that in all the
control simulations it can be verified that by further integrating the system from the final
state x(tf ) the virtual patient will eventually converge to its healthy equilibrium. In the next
section we will formulate the optimal control problem with an L1 type objective and define
the necessary optimality condition of the maximum principle related to problem (OCP) given
in (6.72).
It is important to notice that constraints are handled more easily in the direct method than
in the indirect method where one must derive adjoint equations along with the transversality
and optimality conditions before the TPBVP problem can be solved. Furthermore, in the
indirect method, the presence of state inequality constraints requires a priori knowledge of
the number and duration of constrained arcs which is unknown beforehand [20].
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6.2.4 Optimal Control with L1 type Objective
We now formulate the optimal control problem with an L1 type objective and define the
necessary optimality conditions of Pontraygin’s maximum principle. The L1-type objective
function has the following form:
JL1 = x(tf ) +
∫ tf
0
[
Ax(t) +Bu(t)
]
dt, (6.82)
where x = [x1, x2, x3, x4]
T and where A = [a1, a2, a3, a4] together with B = [b1, b2]
are row vectors with positive constants. Also, x(t) = [P (t), N(t), D(t), Ca]
T ≥ 0 and
u(t) = [up, ua]
T ≥ 0, where ≥ means componentwise.
To ensure that the lowest possible dosing amounts are used to achieve the objective, we
include the input doses, up and ua, in the cost function JL1 above. The mediators N and
Ca are also included in the cost function since the steady state for these values in healthy
patients is assumed to be very low for Ca and zero for N . This inclusion will ensure to keep
the level of inflammatory mediators at lower values. It was also noticed that the optimal
control solver converges faster in the presence of N and Ca in the cost function.
1
Remark 6.3. Note that the existence of optimal controls with state constraints are more
difficult but can be obtained when variations can be done within the admissible set of
controls. For background on problems with state constraints and the corresponding necessary
conditions, see [21, 84]
The consequence of using an objective that is linear in the controls is that the resulting
time-varying controls will be “bang-bang”, meaning that treatment protocols alternate
between the maximum dose of pro- and/or anti-inflammatory therapies and the minimum
(i.e. zero) dose. Singular controls may also arise and will be discussed later. Since we are
1The necessary inclusion here of N and Ca in the objective function differs from that used in our previous
studies using MPC ([24], [108]).
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minimizing the cost of JL1 , the standard Hamiltonian is given by:
H(x, u, λ) = Ax(t) +Bu(t) + λ(t)T (f(x) + g(x)u(t)), λ ∈ R4. (6.83)
In what follows, we characterize the optimal control which is then illustrated in several
simulations where we explore various constraints on the dosing controls as well as mixed
state-control constraints.
Theorem 6.4. (Characterization of the optimal control) Given two optimal controls u∗p, u
∗
a
with the corresponding solutions P ∗, N∗, D∗, C∗a of the ordinary differential equation given
in Eq.(2.1)-Eq.(2.4), there exist adjoint equations associated with the system states given by
λ˙1 = −a1 − λ1
[
a− 2bP − c
d+ eP
+
ceP
(d+ eP )2
− zN
g + C2a
]
− λ2
[ h(nC2a + o)
(nC2a + kP + lN +mD + o)
2
]
; (6.84)
λ˙2 = −a2 − λ1
(
zP
g + C2a
)
− λ2
[ i(nC2a + o)
(nC2a + kP + lN +mD + o)
2
− p
]
− λ3
[ 6qtN11
((sC2a + r)
6 + tN6)2
]
− λ4
[ u(g + C2a)
(g + C2a + wD + gN)
2
]
;
λ˙3 = −a3 − λ2
[ j(nC2a + o)
(nC2a + kP + lN +mD + o)
2
]
+ λ3kd − λ4
[ v(g + C4a)
(g + wD +N)2
]
; (6.85)
λ˙4 = −a4 − 2λ1 zPNCa
(g + C2a)
2
+ λ2
[ 2nCa(hP + iN + jD)
(nC2a + kP + lN +mD + o)
2
]
+λ3
[ 12qsN6(sC2a + r)5
((sC2a + r)
6 + tN6)2
]
− λ4
[ 2(uN + vD)Ca
(gN + wD + C2a + g)
2
− kc
]
; (6.86)
and satisfying the following transversality condition
λ(tf ) =
{∂φ[x(tf )]
∂x
}
= 1. (6.87)
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Furthermore,
u∗p =
⎧⎨
⎩ 0 if b1 + λ2 > 0Nmax if b1 + λ2 < 0 (6.88)
u∗a =
⎧⎨
⎩ 0 if b2 + λ4 > 0Camax if b2 + λ4 < 0 (6.89)
Proof. The adjoint equations and the transversality conditions follow from Pontryagin’s
maximum principle [76]. Differentiating the negative of the Hamiltonian with respect to
the states, P , N , D, and Ca, gives the adjoint system in Eq.(6.84)-(6.86). According to the
maximum principle, the optimality equations are then given by
∂H
∂up
= b1 + λ2 = 0 (6.90)
∂H
∂ua
= b2 + λ4 = 0. (6.91)
These are known as switching functions and if we denote them by
φ1(t) = b1 + λ2 and (6.92)
φ2(t) = b2 + λ4, (6.93)
then the optimal control that minimizes the Hamiltonian becomes
u∗p =
⎧⎨
⎩ 0 if φ1(t) > 0Nmax if φ1(t) < 0 (6.94)
u∗a =
⎧⎨
⎩ 0 if φ2(t) > 0Camax if φ2(t) < 0. (6.95)
As was done in our previous studies, we define Nmax = 0.5 and Camax = 0.62 as
the maximum allowed levels of the variables N and Ca, respectively. This restriction is
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to emulate a realistic bound appropriate in a clinical setting to avoid toxicity effects of
potential overdosing. As will be seen, these maximum bounds are violated when state
constraints are not included in the problem statement. We next provide several numerical
solutions to the optimal control problem with the L1 type objective and discuss issues
regarding when singular controls arise as well as the case necessitating an explicit inclusion
of state constraints. The following weights appearing in the objective function 6.82 for the
L1 case will be used for the various constraint scenarios explored: (b1, b2) = (1, 50) and
(a1, a2, a3, a4) = (100, 5, 30, 10). The largest weights are assigned to the states P and D
since eliminating the pathogen and decreasing the level of damage is our goal.
Numerical results for L1 objective with dosing constraints 0 ≤ up ≤ 0.5 and
0 ≤ ua ≤ 0.62
In this scenario we assume the upper bounds on the dosing input to be the same as those
used in [24]: 0 ≤ up ≤ 0.5 and 0 ≤ ua ≤ 0.62. Figure 6.1 displays the simulation results
of this scenarios, showing the optimal states of Pathogen (P ), the pro-inflammatory state
(N), the level of Damage (D) and the anti-inflammatory state (Ca) in Figure 6.1 (a)-(d)
and the resulting control doses, up and ua, in panels (e)-(f). The pro-inflammatory control
up is provided at maximum level for about half an hour, while the anti-inflammatory dose
ua is followed just after for about one hour. Although not very evident in Figure 6.1, ua is
applied with one sample difference after up.
When a switching function is not zero there is “bang-bang” control and, although the
controls are “bang-bang” for most of the simulation, ua actually portrays a singular control
between time (t1, t2) = (2.354, 23.88). The scaled switching function φ2 shown in Figure
6.1(h) is zero during this interval, unlike φ1 in panel (g) which does not vanish in any
finite open interval. We first demonstrate that the singular control is minimizing and then
demonstrate that an approximation to the singular control gives similar results and provides
a more practical dosing protocol to implement.
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Figure 6.1: (a)-(d) Time courses for optimal states, (e)-(f) control states, and (g)-(h) the
switching functions φ1 and φ2. Control constraints in this simulation which uses an L
1 type
objective are 0 ≤ up ≤ 0.5, 0 ≤ ua ≤ 0.62.
To determine if the singular control generated is minimizing, we derive a solution
corresponding to the singular control. However, the fact that there is no explicit dependence
on the control in either switching function (6.92) or (6.93) makes it problematic to determine
where they vanish and higher order derivatives must be examined in order to derive a solution
that will correspond to the singular control. As mentioned, singular control occurs in the
anti-inflammatory control ua and thus, the switching function corresponding to φ2 will be of
interest. The first derivative of φ2 is given in Eq.(6.96); however, since the control does not
appear in the expression, a second derivative is needed.2
2If φ2 vanishes on (t1 , t2) then we must have φ2 = φ˙2 = φ¨2 = 0 until the first control appears
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φ˙2 = −a4 − 2λ1 zPNCa
(g + C2a)
2
+ λ2
[ 2nCa(hP + iN + jD)
(nC2a + kP + lN +mD + o)
2
]
+λ3
[ 12qsN6(sC2a + r)5
((sC2a + r)
6 + tN6)2
]
− λ4
[
− 2(uN + vD)Ca
(gN + wD + C2a + g)
2
− kc
]
= 0 (6.96)
The second derivative of φ2 is given by Equation (6.97) where the control now appears,
and which φ2 = 0 can be solved to derive the solution corresponding to the singular control.
φ¨2 =
(
−2λ1zNCa
(C2a + g)
2
− 2b1nCah
(nC2a + kP + lN +mD + o)
2
+
4b1nCa(hP + iN + jD)k
(nC2a + kP + lN +mD + o)
3
)
P˙
+ θ1
(
(hP + iN + jD)
(nC2a + kP + lN +mD + o)
− pN
)
+
[ −2b1nCaj
(nC2a + kP + lN +mD + o)
2
+
4b1nCa(hP + iN + jD)m
(nC2a + kP + lN +mD + o)
3
+ b2
(
2vCa
(gN + wD + C2a + g)
2
− 2(2uN + 2vD)Caw
(gN + wD + C2a + g)
3
)]
D˙
+ θ2
(
sc+ (uN + vD)
(gN + wD + C2a + g)
− kcCa
)
− 2λ˙1 zPNCa
(g + C2a)
2
+ λ˙2
[ 2nCa(hP + iN + jD)
(nC2a + kP + lN +mD + o)
2
]
+ θ1up + θ2ua = 0, (6.97)
where
θ1 = −2 λ1zPCa
(C2a + g)
2
− 2b1niCa
(nC2a + kP + lN +mD + o)
2
+
4b1nCa(hP + iN + jD)l
(nC2a + kP + lN +mD + o)
3
+
72qsN5(sC2a + r)
5
((sC2a + r)
6 + tN6)2
λ3 − 144λ3qsN
11(sC2a + r)
5t
((sC2a + r)
6 + tN6)3
+ b2
(
2uCa
(gN + wD + C2a + g)
2
− 2(2uN + 2vD))Cag
(gN + wD + C2a + g)
3
)
(6.98)
and
θ2 = 8
λ1zPNC
2
a
(C2a + g)
3
− 2 λ1fPN
(C2a + g)
2
− 8 λ2(hP + iN + jD)n
2C2a
(nC2a + kP + lN +mD + o)
3
+ 2
λ2(hP + iN + jD)n
(nC2a + kP + lN +mD + o)
2
+ 120λ3
qs2N6(sC2a + r)
4Ca
((sC2a + r)
6 + tN6)2
− λ4
( −(2uN + 2vD)
(gN + wD + C2a + g)
2
+
(4(2uN + 2vD))C2a
(gN + w ∗D + C2a + g)3
)
− 288λ3 qs
2N6(sC2a + r)
10Ca
((sC2a + r)
6 + tN6)3
.
(6.99)
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For singular control to be minimizing, the generalized Legendre-Clebsch condition shown
in (6.100) needs to be satisfied [58].
(−1) ∂
∂ua
d2
dt2
∂H
∂ua
≥ 0 (6.100)
That is, during the simulation, the expression in −θ2 (See Figure 6.1(h)) must be positive
semi-definite. Although not reported here, a plot of −θ2 (See Eq.(6.99)) shows that it is
strictly positive for t ∈ (t1, t2), where t1 = 2.354 and t2 = 23.88, proving the optimality of
the singular arc. If we consider the pro-inflammatory input, up, to be constant then the
singular control part of ua can be easily derived from Eq.(6.97). Note that in all simulations,
up is zero during the interval where a singular control is present in ua.
Figure 6.1(a)-(f) displays results of the simulation. The cost function J6.2.4 associated
with Figure 6.1, the entry and exit times of the singular control, and the final states
corresponding to the simulation are given as follows:
J6.2.4 = 2104.78 t1 = 2.354 t2 = 23.88
P (tf ) = 0 N(tf ) = 0.0061 D(tf ) = 0.025
Ca(tf ) = 0.29
Finally, we consider an approximation to the “bang-bang-singular” control (or what we
term the basic optimal control), where we replace the time course for the singular control
with a constant input, namely zero. In other words, we do not provide any dosing of ua
during the period where the singular control occurred and determine if this approximation is
acceptable in terms of the resulting outcomes of the states. The motivation of replacing the
singular control with a constant is to suggest a more practical implementation of the dosing
protocol.
Figure 6.2 provides the comparison of the simulation using the optimal controls generated
for up and ua (panels (a)-(b) which are the same as in Figure 6.1(a)-(f)) versus the simulation
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Figure 6.2: Comparison of basic optimal control with an approximate control for the L1
objective case with dosing constraints of 0 ≤ up ≤ 0.5 and 0 ≤ ua ≤ 0.62. (a) Generated
optimal controls up and ua and (b) corresponding optimal states. (c) Generated optimal
control up and approximation of optimal control ua and (d) corresponding states. The time
frame displayed in both plots (a) and (c) of the control doses is for tf = 40 hours since
afterward the values of both controls are zero.
where an approximation of the ua control was made for the singular arc (panels (c)-(d)).
Comparison of Figure 6.2 panel (d) with (b) shows that the states Ca and D are the ones
mainly affected by this approximate control case. In other words, changing the level of anti-
inflammatory dose Ca, namely reducing it to zero for that time period, has a direct impact
on the mitigation of damage (D). Thus, a lack of anti-inflammatory mediator at critical
moments results in an increase of the level of damage, which is seen in Figure 6.2(d). In
this particular case, the long-term dynamics of the two simulations are the same; however,
such approximations would need to be done carefully. An improved solution might be to
approximate the singular arc by a piece-wise constant function of say, four pieces which
would better capture the gradual decrease of ua occurring in the singular arc.
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Numerical results for L1 objective with dosing constraints 0 ≤ up ≤ 0.25 and
0 ≤ ua ≤ 0.31
We next explored how a reduction of the maximum allowable doses affected the ability of
the control problem with L1 objective to drive the patient to its healthy state. Thus the
upper bounds on up and ua were reduced to 0 ≤ up ≤ 0.25 and 0 ≤ ua ≤ 0.31, which is half
of the amount used in the previous section. The resulting simulation is given in Figure 6.3
(a)-(b). The numerical information about the cost, exit and entry times for the singular arc,
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Figure 6.3: Comparison of basic optimal control with an approximate control for the L1
objective case with upper bounds on dosing constraints given as upmax = 0.25 and uamax =
0.31. (a) Generated optimal controls up and ua and (b) corresponding optimal states. (c)
Generated optimal control up and approximation of optimal control ua and (d) corresponding
states. The time frame displayed in both plots (a) and (c) of the control doses is for tf = 40
hours since afterward the values of both controls are zero.
as well as the final states corresponding to Figure 6.3 are given by
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J6.2.4 = 2469.904 t1 = 3.363 t2 = 21.02
P (tf ) = 0 N(tf ) = 0.0074 D(tf ) = 0.0326
Ca(tf ) = 0.311
The singular control verifies the Legendre-Clebsch condition in (6.100) for optimality. The
simulation results show an increase in the cost function J6.2.4 when compared to J6.2.4 of the
previous section and this can be explained by the increase of the level of Damage, D, as a
result of decreasing the total dose of the anti-inflammatory mediator, Ca. Similar to what
was done in the previous section, Figure 6.3 (d) displays the outcome of the states when an
approximation of the optimal control input, ua, is made as shown in panel (c).
In either sets of simulations for this and previous section and in either the optimal or
approximate cases, we observe that the level of damage (D) remains such that D ≤ 1 (and
can be verified to approach zero eventually in the absence of further control) and the level
of pathogen (P ) decreases relatively quickly to zero. An interesting pattern we observe is
that each dose associated with an increase of the pro-inflammatory mediator is followed
immediately after by a dose of anti-inflammatory therapy. This behavior can be explained
by the fact that the immune system requires an initial boost of activated phagocytes, N , to
eliminate the pathogen threat, but the resulting inflammation causes some self-harm seen in
the relative increase of tissue damage, D, which then needs the inhibitory effects of CA via
an anti-inflammatory dose, ua, to ensure the decay of damage.
The anti-inflammatory dosing input is applied for a period of time clearly longer than
up. It is interesting to notice in Figure 6.3 that when the maximum allowable doses were
decreased by half, the control doses seems to be applied for a longer duration when compared
to the initial scenario where Nmax = 0.5 and Camax = 0.62. As a consequence of lowering the
intensity of the dose, the optimal control compensates by allowing a longer application. This
behavior was also observed when solving the TPBVP for the L1 problem using the forward
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backward sweep method in [63].
It can also be seen in Figure 6.2 of the previous section that the anti-inflammatory states
do not remain below the upper bound mentioned previously on the anti-inflammatory state
Ca (i.e. Camax = 0.62
3) and the same is used for the simulations of this section given in Figure
6.3, even though the maximum upper bound on the doses for both controls was reduced by
half. Thus, in the next section, we impose state constraints on N and Ca in the problem
formulation.
Numerical results for L1 objective with state and dosing constraints
In this section, we now impose the state constraints on N and Ca we defined earlier of
0 ≤ N(t) ≤ 0.5 and 0 ≤ Ca ≤ 0.62, along with dosing constraints of 0 ≤ up ≤ 0.5 and
0 ≤ ua ≤ 0.62 which are the same dosing constraints of Section 6.2.4. The analysis of
the numerical results obtained when using the state constraints together with the control
constraints would be subject, in most part, to the same discussion as in the section before; the
only difference would be the additional jump conditions on the adjoints and the transversality
condition. To be more pertinent, we will refer the reader to the similar discussion presented
later in section 6.2.5. For the sake of brevity, the details are not provided for this case.
The resulting simulation is given in Figure 6.4 and the numerical information about the
costs and final states corresponding to Figure 6.4 are given by
J6.2.4 = 2393.339 t1 = 2.186 t2 = 4.036
P (tf ) = 0.0000 N(tf ) = 0.0073 D(tf ) = 0.0318
Ca(tf ) = 0.3093
3The max value for Ca was derived from the bifurcation study in [81] of the N/D subsystem. It was
determined in that study that the system loses bi-stability between the healthy and the death state if
Ca > 0.62 with only the healthy state being stable. For this reason, to ensure the presence of a stable death
state the latter bound on Ca is enforced. The max value of N = 0.5 was determined experimentally (through
simulations; See [24])
82
0 10 20 30 40
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
0.
6
Time (Hours)
In
fla
m
m
at
or
y 
D
os
es
up
ua
0 50 100 150
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
Time (Hours)
 S
ta
te
s
P
N
D
Ca
Figure 6.4: Optimal doses and corresponding state trajectories for an L1 type objective
with state constraints 0 ≤ N(t) ≤ 0.5, 0 ≤ Ca ≤ 0.62 together with dosing constraints
0 ≤ up ≤ 0.5 and 0 ≤ ua ≤ 0.62. (a) Dosing profiles for up and ua controls that lead to (b) a
healthy outcome as all states decrease toward background levels. The time frame displayed
in (a) of the control doses is for tf = 40 hours since afterward the values of both controls
are zero.
The simulation in Figure 6.4(a) shows that a singular arc occurs between time t1 = 2.186
and t2 = 4.036, which can be verified as before by checking the resulting function φ2, as the
one given in Figure 6.1(h). The optimality of the singular arc can be derived by verifying the
Legendre-Clebsh condition of (6.100). Notice that 6.4(a) shows that the pro-inflammatory
dose is applied for a duration of almost 20 minutes followed by a rest period of 50 minutes
before the anti-inflammatory dose is injected for a longer duration corresponding to one hour.
Thus far, we have studied optimal control scenarios in which the objective is linear in
the control. In the remainder of this paper the focus will be on deriving the optimal control
doses subject to an objective that is quadratic in the control as well as different constraint
types. A discussion comparing the results of the uses of the different objective functions will
also be given.
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6.2.5 Optimal Control with L2 type Objective
In this section we present numerical simulations of the optimal control problem when the
objective is quadratic in the control.
JL2 = x
T (tf )x(tf ) +
∫ tf
0
[
x(t)TAx(t) + u(t)TBu(t)
]
dt (6.101)
where A and B are matrices with diagonals (a1, a2, a3, a4) and B = (b1, b2) respectively. Also,
x(t) = [P (t), N(t), D(t), Ca]
T ≥ 0 and u(t) = [up, ua]T ≥ 0, where ≥ means componentwise.
We also once again define Nmax = 0.5 and Camax = 0.62 as the maximum allowed levels
of the variables N and Ca, respectively. We provide several numerical solutions to the
optimal control problem with the L2 type objective under various constraint definitions. The
following weights appearing in the objective function (6.101) for the L2 case will be used for
the various constraint scenarios explored in the subsections that follow: (b1, b2) = (1, 20) and
(a1, a2, a3, a4) = (10, 1, 10, 10). Note that the objective function includes the cost at the final
time, φ(x(tf )
2). All other aspects of the numerical settings are as given in the beginning of
Section 6.2.3.
The Hamiltonian for the L2 type objective is given according to
H(x, u, λ) = x(t)TAx(t) + u(t)TBu(t) + λ(t)T (f(x) + g(x)u) (6.102)
where λ(t) = (λ1, λ2, λ3, λ4)
T . While The L1 type objective leads in general to more intricate
analysis involving bang-bang and singular control, the L2 type objective analysis often results
in continuous control, when no state constraints are included. The case of mixed state-control
inequality constraint will be introduced in next section, followed by a section that looks at
separate or pure control and state constraints. For all constraints used in the following
subsections, those associated with N and/or up have a maximum bound of 0.5, while those
associated with Ca and/or ua have a maximum bound of 0.62.
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Numerical results for L2 objective with mixed control-state inequality constraints
Consider the mixed control-state inequality constraints 4 given according to
C1(N(t), up(t)) = up(t) +N(t)− 0.5 ≤ 0 (6.103)
C2(Ca(t), ua(t)) = ua(t) + Ca(t)− 0.62 ≤ 0. (6.104)
Imposing mixed control-sate constraints allows the derived optimal control to account for the
actual value of the states, and hence only the necessary control dose will be administered.
The simulation results for this OCP are given in Figure 6.5 and correspond to the numerical
information about the costs and final states given as follows:
J6.2.5 = 602.67 P (tf ) = 0 N(tf ) = 0.0082 D(tf ) = 0.0376 Ca(tf ) = 0.3216 (6.105)
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Figure 6.5: (a) Optimal doses and (b) corresponding state trajectories for a quadratic
type objective with mixed control state inequality constraints 0 ≤ up(t) ≤ 0.5 − N(t),
0 ≤ ua(t) ≤ 0.62−Ca(t). The time frame displayed in (a) of the control doses is for tf = 40
hours since afterward the values of both controls are zero.
4Note that we adhere to the sign convention in [20]
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Note that both controls are constrained to be positive semidefinite, i.e., 0 ≤ up and
0 ≤ ua. All the constraints are adjoined such that the augmented Hamiltonian in equation
(6.102) can be expressed according to
H(x, u, λ, μ) = H(x, u, λ) + μ1C1(N, up) + μ2C2(Ca, ua)− μ3up − μ4ua. (6.106)
Necessary conditions for minimizing the Hamiltonian can then be derived. The multiplier μ
is given such that it verifies the complementary condition
μi =
⎧⎪⎨
⎪⎩
0 if Ci < 0
μi ≥ 0 if Ci = 0 for i = 1, 2.
(6.107)
The adjoint equations are given in the following compact form
λT = −Hx =
⎧⎪⎨
⎪⎩
−Hx(x, u, λ) if C < 0
−Hx(x, u, λ)− μCx if C = 0;
(6.108)
and more explicitly as follows:
λ˙1 = −∂H
∂P
λ˙3 = −∂H
∂D
(6.109)
λ˙2 = −∂H
∂N
− μ1 λ˙4 = − ∂H
∂Ca
− μ2. (6.110)
The controls up or ua can be derived from the mixed constraints along the constrained arc.
In other words, whenever
C(x, u) = 0 for t ∈ (t1, t2). (6.111)
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Hence, the boundary controls are given by
upb = 0.5−N(t) (6.112)
uab = 0.62− Ca(t). (6.113)
The free controls can be derived from the minimum condition such that
up = − λ2
2b1
(6.114)
ua = − λ4
2b2
. (6.115)
Since the regularity condition is verified, i.e., Cu(x, u) = 0, the multiplier μ follows from the
local minimum condition μ = μ(x, λ) = −Hu(x, λ, ub(x))/Cu(x, ub(x)). In other words, by
μ1 = −2b1up − λ2 (6.116)
μ2 = −2b2ua − λ4, (6.117)
whenever the lower constraints on the controls are not active (i.e. up > 0 and ua > 0).
When the mixed constraints are active, the multipliers μ1 and μ2 are given by substituting
the equation for upb given in (6.112) into (6.116) and similarly for uab of (6.113) into (6.117),
such that
μ1 = −2b1(0.5−N(t))− λ2 (6.118)
μ2 = −2b2(0.62− Ca(t))− λ4. (6.119)
The optimal controls are given as follows
up(t) =
⎧⎪⎨
⎪⎩
− 1
2b1
(λ2 + μ1) if 0 ≤ t ≤ t0 = 1.009
0 if t0 ≤ t ≤ tf = 168;
(6.120)
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ua(t) =
⎧⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎩
0, if 0 ≤ t ≤ t1 = 1.009
−1
2b2
(λ4 + μ2), if t1 ≤ t ≤ t2 = 19
0, if t2 ≤ t ≤ tf = 168.
(6.121)
Note that the mixed control-state constraints, C1 and C2 in equations (6.103) and (6.104),
respectively, are active whenever the controls are not zero; that is, μ1 ≥ 0 and μ2 ≥ 0. For
0 ≤ t ≤ t0 and t1 ≤ t ≤ t2 the switching structure is given by the junction conditions
μ1(t) = −2b1(0.5−N(t))− λ2(t) = 0 (6.122)
μ2(t) = −2b2(0.62− Ca(t))− λ4(t) = 0. (6.123)
The next section presents a scenario where we have pure state constraints on N and Ca
as well as constraints on the upper bounds of the control doses.
Numerical results for L2 objective with pure state and control constraints
Now consider imposing path constraints on the states N and Ca such that N(t) ≤ 0.5 and
Ca(t) ≤ 0.62 ∀t. In addition, we will require as before that the following control constraints
be met: 0 ≤ up ≤ 0.5 and 0 ≤ ua ≤ 0.62. The simulation results for this OCP are given
in Figure 6.6 and correspond to the numerical information about the costs and final states
given as follows:
J6.2.5 = 513.77 P (tf ) = 0 N(tf ) = 0.0071 D(tf ) = 0.0306 Ca(tf ) = 0.3065
Consider the last inequality in the (OCP) problem S(x(t)) ≤ 0, given specifically for this
case as
S1(N(t)) = N(t)− 0.5 ≤ 0 (6.124)
S2(Ca(t)) = Ca(t)− 0.62 ≤ 0. (6.125)
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Figure 6.6: (a) Optimal doses and (b) corresponding state trajectories for a quadratic type
objective with state path constraints 0 ≤ N(t) ≤ 0.5, 0 ≤ Ca ≤ 0.62. The time frame
displayed in (a) of the control doses is for tf = 40 hours since afterward the values of both
controls are zero.
Whenever one of the constraints becomes active on a subinterval we have
Si(x(t)) = 0 for all t ∈ (t1, t2) ⊂ [0, 168]. (6.126)
Let r be the order of the state constraint; that is, the smallest non-negative numbers
necessary for the control to first appear [90]. It is straightforward to see that r = 1 and
furthermore,
S˙2(x, ua) = C˙a = sc +
uN + vD
g + C2a + gN + wD
− μcCa + ua(t). (6.127)
The state constraint satisfies the following regularity condition
∂
∂ua
S˙2(x, ua) = (0, 1) = (0, 0). (6.128)
Remark 6.5. We can derive similar conditions for S1. We will focus on the state Ca since
that is the only state that becomes active.
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The boundary control uab on the constrained arc can be derived from (6.127) by also
replacing Ca(t) = 0.62 such that
uab = −sc −
uN + vD
g + 0.622 + gN + wD
+ 0.62μc. (6.129)
The augmented Hamiltonian is given according to
H(x, u, λ, λs) = x(t)TAx(t) + u(t)TBu(t) + λ(t)T (f(x) + g(x)u) + λsS(x), (6.130)
+ μ1(up(t)− 0.5) + μ2(ua(t)− 0.62)− μ3up − μ4ua, (6.131)
where λs = [λsp, λsa] is a row vector and S(x) = [S1, S2]
T is a column vector. The adjoint
equation can be formulated in a similar fashion as in (6.108). The multiplier λsa needs to
verify the complementary slackness condition [90] given as:
λsa =
⎧⎪⎨
⎪⎩
0 if S2 < 0
λsa ≥ 0 if S2 = 0.
(6.132)
The adjoint equation corresponding to the dynamic equation C˙a is given by
λ˙4(t) = − ∂H
∂Ca
− λsa. (6.133)
The minimum condition can be derived as in the previous section when 0 = ∂H
∂up
= 2b2ua+λ4.
On the boundary arc, ua is constant (See Figure 6.7), and we get λ˙4 = 0 as can be seen in
the same figure. The multipliers λsa can be derived from (6.133) according to
λsa = − ∂H
∂Ca
∣∣∣∣∣
Ca=0.62
. (6.134)
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The optimal controls are given as follows
up(t) =
⎧⎪⎨
⎪⎩
0.5 if 0 ≤ t ≤ t0 = 0.3363
0 if t0 ≤ t ≤ tf = 168;
(6.135)
ua(t) =
⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
0, if 0 ≤ t ≤ t1 = 1.009
0.62, if t1 ≤ t ≤ t2 = 2.186
uab , if t2 ≤ t ≤ t3 = 17.32
−1
2b2
(λ4), if t3 ≤ t ≤ t4 = 17.66
0, if t4 ≤ t ≤ tf = 168.
(6.136)
The jump conditions and transversality condition are given, respectively, as
λ(ts−) = λ(ts+) + βsSx(x(ts)) βs ≥ 0 and (6.137)
λ(tf ) = (2P (tf ), 2N(tf ), 2D(tf ), 2Ca(tf )). (6.138)
Figure 6.7 displays the computed anti-inflammatory dose ua and the evolution of the
constrained state Ca together with the adjoint variable λ4 and the multiplier λs corresponding
to the state constraint S(x(t)) = Ca(t) − 0.62. The Figure outlines that the constraint on
Ca becomes active in the interval [2.186, 17.32]. One can also see in the same figure that
the multiplier λs satisfies the complementary condition (6.132). The jump discontinuity at
t1 = 2.186 on the control ua for this L
2 optimal control is nonintuitive since one would
expect a continuous control as in the scenario of the previous section; however, this result is
common when using pure state constraints (See Eq. (6.137)). The scaled adjoint variable λ4
in Figure 6.7, which is associated with the differential equation x˙4, has a jump discontinuity
at the time the constraint becomes active.
Remark 6.6. The objective functional value corresponding to section 6.2.5, which is
associated with the mixed control-state constraints is higher than the one given in section
6.2.5, that is associated with pure control and state constraints. In the case that imposes
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Figure 6.7: Numerical solutions of the state and control constrained problem with L2
objective. Top row: control ua(t) and constrained anti-inflammatory state Ca(t). Bottom
row: The scaled adjoint λ4 corresponding to the state Ca(t) together with the multiplier λsa
corresponding to the constraint S(x(t)) = Ca(t) − 0.62. The time frame displayed in the
figures is for tf = 40 hours since afterward the values of the control inputs are zero.
mixed control-state inequality constraints, the maximum allowed doses are updated based
on the the actual states of Ca and N . For instance, if at a sampling time, t, Ca(t) = 0.62
the upper bound on ua is zero and similarly, if N(t) = 0.5, then the upper bound on up is
zero. However, this constraint formulation is more restrictive with the amount of doses given
which results in an increase in the damage response (Figure 6.5) compared with the pure
state and control constraints (Figure 6.6), which may require additional or longer dosing to
achieve a successful outcome.
6.3 Summary
In this work, we determined successful treatment protocols to regulate the inflammatory
response modeled with an ordinary differential equations system through solving the optimal
control problem using a direct approach. Two cases were considered regarding the form of
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the objective functional: linear versus quadratic in the control. The results of the direct
numerical methods used are in agreement with the characterization of the optimal control. A
noticeable difference was not observed in the way the controls are provided when considering
an L1 versus L2 type objective. In either case, it was observed that state constraints needed
to be included explicitly in order for the states not to exceed the prescribed bounds set for
realistic considerations. The case where singular control appears is also addressed when the
objective is linear in the control, the optimality of the singular arcs was demonstrated by
verifying the Legendre-Clebsch condition.
The dynamics of inflammatory immune response is more complex and varied than
represented by the reduced inflammatory model considered in this study, however the
obtained computational results can provide insight into possible treatment strategies and
the methods could prove to be useful tools to incorporate in future practice. In particular,
one can see a prevailing pattern in the way the doses are implemented in this study and is in
agreement with results of previous computational studies ([24], [108]). Whether considering
the solution for the L2 or L1 type objective, generally speaking, a successful control strategy
is marked by an initial bolus of a pro-inflammatory control (up) administered first to quickly
eliminate the harmful effect of the pathogen, followed just after by a two phase application
of the anti-inflammatory mediator (ua). In the first phase, a bolus of anti-inflammation is
applied, followed by a longer duration application of ua, but with a very small amount. The
similar patterns in the generated control doses up and ua when solving for either type of
objective seems clinically reasonable when thinking that in the presence of a pathogen, the
pro-inflammatory mediators will naturally increase to try to eliminate the pathogen, which
in turn will cause a certain increase in the level of collateral tissue damage which incites
further inflammation. If not controlled, this positive feedback may result in the death of
the patient. Fortunately, however, the response also includes a release of anti-inflammatory
mediators which helps alleviate the harmful effect of the pro-inflammation, ultimately driving
the patient to its healthy equilibrium in the absence of further pathogen threat. So essentially,
the dynamic necessary for stabilizing a patient with sever inflammation is reflected exactly
by increasing the pro-inflammatory effects with input up followed just after by a dose of
anti-inflammatory mediator, with input ua. It is important to notice in our study that we
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assume the dosages represent the actual concentrations with idealized effect on patient; that
is, we do not assume any model for the pharmacokinetics or pharmacodynamics. The effects
of these two phenomena on optimal protocols could be included in further study. Future
work would also benefit from the use of an immune response model that displays similar
complex behavior as the reduced model but does not lump too many variables together to
see how the obtained results would then relate to what has been presented in this work.
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Chapter 7
Towards a model free feedback control
synthesis for treating acute
inflammations
An effective and patient-specific feedback control synthesis of an inflammatory immune
response is still an ongoing research area. A strategy consisting of manipulating a pro and
anti-inflammatory mediator is considered here. Some promising model-based techniques
have already been proposed, as seen in previous chapters. They suffer unfortunately from
a quite difficult calibration due to the heterogeneity of individual patient responses and
immune functions even under similar initial conditions. A new model-free control approach
and its corresponding “intelligent” controllers are therefore exploited in this biomedical
context. A crucial feature of the proposed control problem is the following one: the two most
important outputs which must be driven to desired states are sensorless. This difficulty is
overcome by assigning suitable reference trajectories to the two other outputs with sensors.
A mathematical model, via ordinary differential equations, is nevertheless employed as a
“virtual” patient for in silico testings. Several computer simulations with respect to most
varied situations are displayed. They highlight the effectiveness of our viewpoint.
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7.1 Justification of the model-free approach: A brief
sketch
7.1.1 Introduction
Instead of trying to get an accurate nonlinear model given according to
x˙ = f(x, u, t) (7.1)
y = g(x) (7.2)
Replace the unknown global description by the ultra-local model :
y˙ = F + αu (7.3)
where
• the control and output variables are u and y,
• the derivation order of y is 1 like in most concrete situations,
• α ∈ R is chosen by the practitioner such that αu and y˙ are of the same magnitude.
The following explanations on F might be useful:
• F is estimated via the measure of u and y,
• F subsumes not only the unknown system structure but also any perturbation.
7.1.2 Intelligent controllers
The loop is closed by intelligent proportional controller, or iP,
u = −F − y˙
∗ +KP e
α
(7.4)
where
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• y is the reference trajectory,
• e = y − y is the tracking error,
• KP is the usual tuning gain.
With a “good” estimate Fest of F , i.e., F − Fest  0, Equations (7.3)-(7.4) yield
e˙+KP e = F − Fest  0
Thus e(t)  e(0) exp(−KP t). It implies that
lim
t→+∞
y(t)  y(t)
if, and only if, KP > 0. In other words, an excellent tracking of the reference trajectory
is ensured. This tracking is moreover quite robust with respect to uncertainties and
disturbances which are numerous in our medical setting. This is explained by the fact that
F in Equation (7.3) encompasses “everything,” without trying to distinguish between its
different components. Here, sensorless outputs must be driven in order to cure the patient.
Without any reliable modeling, employing an observer, i.e., a state estimator, would not be
helpful. This tough problem is solved by assigning suitable reference trajectories to some
measured system variables.This feedforward viewpoint is borrowed from the flatness-based
control setting [38].
7.1.3 Justification of the ultra-local model
We first justify the ultra-local model (7.3). For notational simplicity’s sake, let us restrict
to a system with a single control variable u and a single output variable y. Assume that the
system is a causal, or non-anticipative, functional, i.e., for any time instant t > 0,
y(t) = F (u(τ) | 0 ≤ τ ≤ t) (7.5)
where F depends on
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• the past and the present, and not on the future,
• various perturbations,
• initial conditions at t = 0.
A popular, also in biology, representation of rather general nonlinear functionals is
provided by Volterra series (see, e.g., [57]):
y(t) =h0(t) +
∫ t
0
h1(t, τ)u(τ)dτ+∫ t
0
∫ t
0
h2(t, τ2, τ1)u(τ2)u(τ1)dτ2dτ1 + . . .∫ t
0
. . .
∫ t
0
hν(t, τν , . . . τ1)u(τν) . . . u(τ1)dτν . . . dτ1
+ . . .
Solutions of quite arbitrary ordinary differential equations, related to input-output behaviors,
may be expressed as Volterra series (see, e.g., [37]). Let
• I ⊂ [0,+∞[ be a compact subset,
• C ⊂ C0(I) be a compact subset, where C0(I) is the space of continuous functions
I → R, which is equipped with the topology of uniform convergence.
Consider the Banach R-algebra S of continuous causal functionals (7.5) I × C → R. If a
subalgebra contains a non-zero constant element and separates points in I × C, then it is
dense in S according to the classic Stone-Weierstraß theorem (see, e.g., [88]). Let A ⊂ S
be the set of functionals which satisfy an algebraic differential equation of the form
E(y, y˙, . . . , y(a), u, u˙, . . . , u(b)) = 0 (7.6)
where E is a polynomial function of its arguments with real coefficients. It has been proved
in [103] that the conditions of the Stone-Weierstraß theorem are satisfied: A is dense in S.
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Assume therefore that our system is “well” approximated by a system defined by Equation
(7.6). Let ν be an integer, 1 ≤ ν ≤ a, such that
∂E
∂y(ν)
≡ 0
The implicit function theorem yields locally
y(ν) = E(y, y˙, . . . , y(ν−1), y(ν+1), . . . , y(a), u, u˙, . . . , u(b))
It may be rewritten as
y(ν) = F + αu (7.7)
In most concrete situations, here for instance, the order ν = 1 of derivation, as in
Equation(7.3), is enough. See [103] for an explanation and for some examples where ν = 2.
7.1.4 Closing the loop
If ν = 1 in Equation (7.7), we are back to Equation (7.3). The loop is closed with the
intelligent proportional controller (7.4).
7.1.5 Estimation of F
Any quite general function [a, b] → R, a, b ∈ R, a < b, may be approximated by a step
function Fapprox, i.e., a piecewise constant function (see, e.g., [87]). For estimating a suitable
approximation of F in Equation (7.7), the question boils down therefore to the identification
of the constant parameter Φ in
y˙ = Φ+ αu (7.8)
Employ a recent real-time algebraic estimation/identification techniques ([39, 93]). Equation
(7.8) yields with respect to the well known notations of operational domain (see, e.g., [107]):
sY =
Φ
s
+ αU + y(0)
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We get rid of the initial condition y(0) by multiplying both sides on the left by d
ds
:
Y + s
dY
ds
= −Φ
s2
+ α
dU
ds
The product by s corresponds in the time domain to the derivation with respect to time,
which is known to be most sensitive to noise corruptions. Multiply therefore both sides on
the left by s−2: in order to replace derivations by integrations with respect to time, which
are quite robust with respect to noises (see [36] for more explanations). Recall that in d
ι
dsι
,
where ι ≥ 1 is an integer, corresponds in the time domain to the multiplication by (−t)ι.
Then
Fest(t) = − 6
τ 3
∫ t
t−τ
[(τ − 2σ)y(σ) + ασ(τ − σ)u(σ)] dσ (7.9)
where τ > 0 might be quite small. This integral may of course be replaced in practice by a
classic digital filter.
There are of course other formulae for obtaining an estimate of F . Closing for instance
the loop with the iP (7.4) yields:
Fest(t) =
1
τ
[∫ t
t−τ
(y˙ − αu−KP e) dσ
]
(7.10)
Remark 7.1. Measurement devices are always corrupted by noises of various natures (see,
e.g., [100]). Those noises are usually described via probabilistic/statistical laws that are
difficult to write down in most concrete situations. Follow [36] where nonstandard analysis
is used: the noise is related to quick fluctuations around zero [29]. Such a fluctuation is
a Lebesgue-integrable real-valued time function F which is characterized by the following
property: its integral
∫ τf
τi
F(τ)dτ over any finite time interval is infinitesimal, i.e., “very
small.”. Therefore noises are attenuated thanks to the integrals in Formulae (7.9)-(7.10).
7.2 Computer Simulation
In order to evaluate the performance of the proposed control strategy, we use a set of 1000
virtual patients generated in [24]. The virtual patients were generated in that study by
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choosing six parameters of the model and two initial conditions (for P and Ca) in order
to differ among them. The reference values are given in Table I of [80]. The values
of these parameters and initial conditions were generated from a uniform distribution on
defined parameter ranges or on a range that was +/-25% of the (mean) reference value.
The remaining parameters retained the same values as those in the reference set. The set
of patients was classified with respect to their outcome after an open loop simulation for
a long enough time to numerically determine outcome without ambiguity. Of the 1000
virtual patients, 369 did not resolve the infection and/or inflammatory response on their
own and succumbed to a septic (141) or aseptic (228) death outcome. On the other hand,
631 exhibited a healthy outcome of which there were two distinct subsets:
1. 379 of the 631 healthy virtual patients did not necessitate treatment intervention
because their inflammatory levels did not exceed a specified threshold, i.e. N(t) ≤ 0.05,
set in [24]) and these were excluded from receiving treatment and from the in silico
study.
2. The remaining 252 of these patients did surpass the specified threshold, i.e., N(t) ≥
0.05, and are included to receive treatment; though, without treatment, these would
be able to resolve to health on their own. An important issue for those patients is then
not to harm them with treatment.
Thus, 621 of the 1000 generated virtual patients receive treatment via our control design.
Once a suitable reference trajectory is provided for the states with sensors, the derivation of
the control part is straightforward which we now discuss.
7.2.1 Control design
As in previous control studies using this model, we assume that the state components P
and D in Equations (2.1) and (2.4) are not measurable whereas the states N and Ca, in
Equations (2.2) and (2.4), respectively are:
• easily measured,
• mostly influenced by the control variables up and ua, respectively.
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Introduce therefore two Equations of type (7.3):
N˙ = F1 + αpup(t) (7.11)
C˙a = F2 + αaua(t). (7.12)
Let us emphasize that, like in [61], the above two ultra-local systems may be “decoupled” so
that they can be considered as monovariable systems. It should be nevertheless clear from
a purely mathematical standpoint that F1 (resp. F2) is not necessarily independent of ua
(resp. up). The two corresponding iPs (7.4) then read
up = −F1,est − N˙
∗ +KP1ep
αp
(7.13)
ua = −F2,est − C˙
∗
a +KP2ea
αa
, (7.14)
The tracking errors are defined by
ep = N −N∗ and ea = Ca − C∗a .
where N∗ and C∗a represent the reference trajectories corresponding to pro and anti-
inflammatory measurements N and Ca, respectively. As already explained in the intro-
duction, a good estimate of the function Fest, that encapsulate all the model uncertainties
and disturbances, would ensure exponential stability of the closed loop system. F1,est and
F1,est are estimated according to section 7.1.5. See Figure 7.1 for the corresponding block
diagram.
Algorithm 5 provides a good summary on the functioning of our regulation. Note that
the same design procedure can lead to the derivation of the control ua, however this time we
associate the measurement Ca to the control ua (See equation (7.12))
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Algorithm 5 Model-free Control
Step 1: Initialization, k = 0
up(0) = 0, define reference trajectories N
∗, initialize Kp and α, fix the sampling time Te
For 1 ≤ k ≤ Tf
Step 2, : Get measurements of N and up,
Step 3 Estimation of F:
Estimate F according to a discrete implementation of equation (7.9)
Step 4: Close the loop according to equation (7.13) and return to Step 2
7.2.2 Results without noise corruption
We first, examine the performance of our control approach with respect to a set of virtual
patients with their corresponding initial conditions. The robustness of the approach with
the addition of corrupting measurement noise will be discussed afterwards. In what follows,
the reference trajectories which are inspired from [8], correspond to the measurable states
N and Ca. They will be highlighted in dashed lines.
The simulations for all patients were performed under the following conditions:
• a sampling time of 1 minute,
• αp = 1, αa = 10 in Equations (7.11)-(7.12),
• KP1 = KP2 = 0.5 in Equations (7.13)-(7.14),
• 250 hours simulation time, to numerically determine outcome without ambiguity,
though we stress that our control objectives were reached in less than 250 hours.
The use of the same reference trajectory for all simulations will emphasize the robustness
of the proposed control approach with respect to the variability among virtual patient
parameter values and initial conditions. Figure 7.2 represents a successful outcome related
to 92 out of 141 cured1 septic patient, when applying a control given by Figure 7.3. The
patients that converge to the septic region as explained in Section 7.2.2, where all the state
of the virtual patient are high, are obviously the ones we haven’t been able to cure. If we
1Cured patients are those in which the final state converged to the healthy equilibrium discussed when
we introduced the inflammatory model
103
Figure 7.1: Block diagram of the model free control design
zoom in the first hours, we can see that the controls up vary mainly in terms of its amplitude,
similar remarks can be made for ua. While keeping analyzing the control ua, we can see that
it is applied for a longer period of time, however with small amount. This was not noticed
with the optimal controls study in [10]. That is why, it was interesting to see if restraining
to provide this small amount dose would have a large impact on the result. Surprisingly, it
has been observed that constraining the anti-inflammatory mediator ua to be zero after 28
hours does not affect at all the number of cured patients. This is important to know in order
to prevent an infusion over a longer period of time.
Table 7.1 displays the results from our study for the 621 patients that qualified for
therapy. The first column displays the outcomes in the absence of intervention, which we
call the placebo outcome. Without intervention, 40% (252) will resolve to a healthy outcome,
while the remaining 60% (369) fall into one of the two unhealthy outcome categories. We use
the total of 369 unhealthy placebo patients to determine the percentage of those rescued via
the treatment. Figures 7.2 and 7.3 display the time courses for the sensorless states, P and
D, which were guided via the reference trajectories for the states with sensors, N and Ca,
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Figure 7.2: Dashed (- -) curves in the panels for the variables N and Ca denote the reference
trajectories used in the simulation. The various colored curves display the closed loop state
responses for the set of 141 septic patients, of which 92 were cured.
Figure 7.3: Time evolution of the control up and ua for the set of septic patients. The
zoomed plot for up provides more details on the duration of the control dose, the x-axis is
shown for two hours only since it is zero for the remaining time
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along with the corresponding control input. The results are reminiscent of [8, 9, 24]: Apply
first a large shot of pro-inflammatory up, which is followed by a soothing effect provided by
an anti-inflammatory dose ua. The latter helps keeping the level of damage to an acceptable
level. The information we can derive from Table 7.1 is that the control strategy obviously
Table 7.1: Result of the immune therapy
Therapy Type: Placebo Model-free control therapy
Percentage Healthy: 40% (252) 85.66% (518)
Percentage Aseptic: 37% (228) 6.4% (40)
Percentage Septic: 23% (141) 7.8% (49)
Percentage Harmed (out of 252) n/a 0% (0/252)
Percentage Rescued (out of 369) n/a 75.88% (266/369)
Figure 7.4: Dashed (- -) curves in the panels for the variables N and Ca denote the reference
trajectories used in the simulation. The various colored curves display the closed loop state
responses for the set of 228 aseptic patients, of which 188 were cured.
improves the percentage of cured patients when compared to the placebo case. Our therapy
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Figure 7.5: Time evolution of the control up and ua for the set of septic patients. The
zoomed plot for up provides more details on the duration of the control dose, the x-axis is
shown for two hours only since it is zero for most of the time
rescued 85.66% of the total patient population (621) and 75.88% of the combined septic and
aseptic population (369). It is also interesting to notice that 0% of the healthy patients have
been harmed. Figures 7.4 shows the evolution of the unobservable state P and D together
with the measured states corresponding to N and Ca for a set of 228 aseptic patients in which
188 were able to recover from an aseptic outcome, when the generated controls in Figure 7.5
are applied, i.e., the pathogen P and the level of damage D are driven to zero. Again, one
can observe from Figure 7.4 that some trajectories diverge to the unhealthy aseptic region,
where the pathogen is known to have a zero value while the other state variables are at high
level. Overall, we can notice that the simulation results of both septic and aseptic population
set are very encouraging when one considers only a unique reference trajectory and multiple
initial conditions. The absence of perfect tracking should not be seen as a weakness of the
model free control approach, as the control objective has been attained in most scenarios.
One of the important features of the presented data driven control approach is the necessity
to have a suitable choice for the reference trajectories of concern. to be more explicit, a naive
choice of the reference trajectory, e.g., an exponential decaying to zero for Nref and another
converging to the steady state value 0.125 exponentially for Caref would not satisfy the
control objective, since first, one would notice that the generated control doses are negative,
and second, the level of pathogen will converge to its maximum allowable value. The reason
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for this behavior can be explained by the fact that the iP controller is only concerned
about minimizing the tracking error without imposing any constraints on the control. The
solution to the problem is not trying to impose constraints on the control, simply because
the actual approach is not formulated as an optimization problem, 2 however choosing a
reference trajectory that will account for the correct dynamics of the inflammatory model
will eventually generate the correct doses, that is, if one would for example chose a reference
with a smaller amplitude or with slower rising dynamic, other than what is presented in this
work, then it is highly probable that the patient would not converge to its healthy state with
respect to the generated control doses received. Similar remarks can be made to Figure 7.5
as discussed previously for the septic set of patients. It is not surprising to notice a very
close pattern with respect to the generated control doses for both sets of septic and aseptic
patients, which can be explained in part by the similar control objective of tracking the same
reference trajectory and also because of what has been discussed before regarding how the
dynamics of the inflammatory response that is necessary in order to eliminate the pathogen
without incurring a significant damage.
7.2.3 Results with noise corruption
Consider the effects of the corrupting measurement noises on our control synthesis. Like in
many academic studies only a white Gaussian noise (see, e.g., [19, 78]) is taken into account.
Otherwise the same setting as before is kept. Figure 7.6 and 7.7 display the states and the
corresponding controls for a set of 141 septic patients in which 90 were cured.
The addition of measurement noise with 10−6 variance seems not to change the outcome
for the septic set of patients except for only two patients, when compared to the initial
simulation where no noise was included. However, for the aseptic set of patients, we notice
that there is a difference of 16 additional patients that did not survive.
Remark 7.2. For the actual simulation with measurement noise, there are mainly two
important remarks to make with regards to the discussion of previous section. First, for the
case of septic patient, restraining the control up and ua to be zero after 2 hours and 28 hours,
2Allowing the control to be only positive semidefinite will result in a zero control all the time.
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Figure 7.6: Dashed (- -) curves in the panels for the variables N and Ca denote the
reference trajectories used in the simulation. The various colored curves display the closed
loop state responses for the set of 141 aseptic patients, of which 90 were cured. Note that
the measurements N and Ca were corrupted with Gaussian noise
Figure 7.7: Time evolution of the control up and ua for the set of aseptic patients when
the measurements N and Ca were corrupted with Gaussian noise. The zoomed plot for up
provides more details on the duration of the control dose, the x-axis is shown for two hours
only since it is zero for the remaining time
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Figure 7.8: Dashed (- -) curves in the panels for the variables N and Ca denote the
reference trajectories used in the simulation. The various colored curves display the closed
loop state responses for the set of 228 aseptic patients, of which 172 were cured. Note that
the measurements N and Ca were corrupted with Gaussian noise
Figure 7.9: Time evolution of the control up and ua for the set of 228 aseptic patients when
the measurements N and Ca were corrupted with Gaussian noise. The zoomed plot for up
provides more details on the duration of the control dose, the x-axis is shown for two hours
only since it is zero for the remaining time
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respectively, will not affect the number of cured patient considerably since 89 patients were
cured. One would fail to obtain similar result when altering in the same way the control for
the aseptic case. Although not reported here, one would notice a drop of around 45 patient
when compared to the 172 cured.
What it can be concluded from the presented simulation results, in regards to the data
driven control approach we used, is the necessity to understand the process we are controlling
since in general, one usually does not know enough about the given biological process to have
a detailed mathematical model, and design a suitable control algorithm. For that reason,
the MFC control approach helps alleviate the requirement to have a model with multiple
parameters that are hard to estimate or one that is accurate enough for a specific application,
and instead, it relies on empirical design and intuition to reach its objective.
Table 7.2: Result of the immune therapy with measurement noise
Therapy Type: Placebo Model-free control therapy
Percentage Healthy: 40% (252) 82.76% (514)
Percentage Aseptic: 37% (228) 9.02% (56)
Percentage Septic: 23% (141) 8.21% (51)
Percentage Harmed (out of 252) n/a 0% (0/252)
Percentage Rescued (out of 369) n/a 71% (266/369)
7.2.4 Further simulation with model free control
In this section we will simulate one virtual patient and provide the generated control doses.
The interest here is to show the precision of the approximation of the nonlinearities of the
immune model that are supposed to be captured in the introduced terms given by F1,est
and F2,est. From Figure 7.10 one can clearly see that the estimation is almost perfect if we
disregard the first iterations that the proposed control approach needs for convergence. We
can verify the error on the estimate of the nonlinearities and their approximation in Figure
7.11. The error converges very fast to zero. This explains the efficiency of the model free
control for dealing with nonlinear systems.
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Figure 7.10: Upper part: state trajectories together with corresponding control doses.
Lower: Nonlinear part NL1 and NL2 together with their approximation given by F1 and F2
respectively
7.3 Concluding remarks
This study is proposing a new data-driven control approach to regulate the state of an
inflammatory immune response in presence of pathogenic infection. The performance of the
proposed control with respect to the parameter variability of a set of 621 virtual patients
is investigated. The results in the presence of measurement noises are also depicted and
discussed. The fact of using a single reference trajectory to model the inflammatory dynamics
necessary with the objective to cure every patients, and be able with it to reach such results,
proves beyond any doubt the robustness to parameter variability and noise disturbances.
The downside of the proposed control to this specific application is the necessity to apply
the control for a longer period of time although with small doses. We have seen however that
restraining from providing this small dose does not affect the outcome of the states when
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Figure 7.11: Left: Estimation error of F1 − F1,est. Right: Estimation error of F2 − F2,est
no measurement noise is used, it did however for the scenarios with measurement noises.
We want to emphasize the importance of a suitable choice for the reference trajectory and
further studies may provide better insight in this direction.
Past successes of the model-free control feedback synthesis in so many realistic case-studies
should certainly be viewed as encouraging for the future development of our approach to
the treatment of inflammation. Let us add the following point which might be of some
interest. The use of model-free control seems to be simpler from both theoretical and
practical standpoints when compared to model-based control designs. This fact, which
follows from the content, seems to be new in the the epistemology of biomedicine. It needs
of course to be further analyzed in order to be confirmed.
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Chapter 8
Conclusions and future work
The objective of this thesis work was to develop control algorithms to stabilize the
inflammatory immune response given the various constraints of limited measurements and
parameter variability from one virtual patient to another. First we successfully shown
that the reduced inflammatory model was locally controllable, observable and the model
parameters are identifiable when the state values are around the equilibrium healthy state.
We followed by studying well known nonlinear filters and established the performance of
the particle filter for estimating the states of the system based only on the pro and anti-
inflammatory measurements. The particle filter theory helped in understanding better the
functioning of the particle Markov chain Monte Carlo consisting of the particle Metropolis-
Hastings. The later has been useful in providing a good estimate of the unknown parameters.
We then determined successful treatment protocols to regulate the inflammatory response
modeled with an ordinary differential equations system through solving the optimal control
problem using a direct approach. Two cases were considered regarding the form of the
objective functional: linear versus quadratic in the control. The results of the direct
numerical methods are in agreement with the characterization of the optimal control. A
prevailing pattern in the way the inflammatory doses are implemented has been determined.
Whether considering the solution for the L2 or L1 type objective, generally speaking, a
successful control strategy is marked by an initial bolus of a pro-inflammatory control (up)
administered first to quickly eliminate the harmful effect of the pathogen, followed just after
by a two phase application of the anti-inflammatory mediator (ua). As opposed to model
114
based control we decided to focus on a new data-driven control approach to regulate the
states of the inflammatory model. The performance of the proposed control with respect
to the parameter variability of a set of 621 virtual patients were investigated. The results
in the presence of measurement noises were also discussed. The promising results obtained
with model free control needs to be investigated more and implemented in a setting where
real data are available for measurements.
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